Hope Rugo
#58,214
Most Influential Person Now
American oncologist
Hope Rugo's AcademicInfluence.com Rankings
Hope Rugophilosophy Degrees
Philosophy
#3919
World Rank
#6254
Historical Rank
#1196
USA Rank
Logic
#1505
World Rank
#2272
Historical Rank
#446
USA Rank
Download Badge
Philosophy
Hope Rugo's Degrees
- Doctorate Medicine University of Pennsylvania
- Bachelors Biology Stanford University
Similar Degrees You Can Earn
Why Is Hope Rugo Influential?
(Suggest an Edit or Addition)According to Wikipedia, Hope S. Rugo is professor of medicine and the director of the breast oncology clinical trials program at the University of California at San Francisco, and an investigator of SPORE in the Bay Area.
Hope Rugo's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. (2012) (2045)
- Palbociclib and Letrozole in Advanced Breast Cancer. (2016) (1641)
- Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer (2018) (1567)
- Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. (2011) (1476)
- Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. (2005) (1308)
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation (2018) (1157)
- Alpelisib for PIK3CA‐Mutated, Hormone Receptor–Positive Advanced Breast Cancer (2019) (1081)
- Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. (2010) (924)
- Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial (2017) (713)
- Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. (2014) (671)
- 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). (2017) (661)
- Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. (2011) (645)
- Breast Cancer—Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual (2017) (627)
- Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. (2009) (622)
- Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. (2019) (616)
- Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. (2020) (615)
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial (2020) (595)
- ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)† (2014) (566)
- Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer (2013) (539)
- Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. (2012) (535)
- 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) (529)
- The cancer glycocalyx mechanically primes integrin-mediated growth and survival (2014) (525)
- Cancer-Related Fatigue, Version 2.2015. (2015) (510)
- NCCN Practice Guidelines for Cancer-Related Fatigue. (2000) (489)
- Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. (2015) (483)
- T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. (2019) (481)
- Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. (2008) (481)
- Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. (2005) (469)
- Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study (2019) (464)
- Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. (2014) (459)
- Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. (2018) (443)
- MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer (2017) (442)
- TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. (2012) (430)
- Sacituzumab Govitecan‐hziy in Refractory Metastatic Triple‐Negative Breast Cancer (2019) (427)
- Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. (2016) (424)
- Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. (2016) (422)
- Leukocyte composition of human breast cancer (2011) (405)
- Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis (2013) (391)
- Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study (2019) (368)
- A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. (2012) (332)
- A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer (2011) (331)
- TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. (2015) (320)
- Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. (2020) (319)
- Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657) (2011) (318)
- Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. (2012) (317)
- Immune microenvironments in solid tumors: new targets for therapy. (2011) (307)
- Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. (2017) (305)
- RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. (2011) (302)
- Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. (2021) (297)
- Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER (2011) (296)
- Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial. (2017) (293)
- A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). (2011) (265)
- MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. (2005) (265)
- Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. (2022) (260)
- Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. (2005) (258)
- Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer (2013) (255)
- Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. (2014) (252)
- Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer (2018) (224)
- ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. (2021) (215)
- Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE‐158 and KEYNOTE‐028 studies (2020) (215)
- 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). (2016) (208)
- Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2. (2016) (205)
- Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. (2018) (203)
- TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer. (2018) (200)
- Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. (2001) (200)
- Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. (2014) (198)
- Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up (2019) (192)
- Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. (1999) (179)
- Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3). (2016) (176)
- TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer (2008) (176)
- Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 (2021) (175)
- Management of Cancer Cachexia: ASCO Guideline. (2020) (170)
- Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). (2015) (156)
- Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. (2019) (156)
- Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer: A Phase 1b Clinical Trial (2019) (156)
- MRI Phenotype Is Associated With Response to Doxorubicin and Cyclophosphamide Neoadjuvant Chemotherapy in Stage III Breast Cancer (2001) (155)
- NCCN Guidelines Insights: Breast Cancer, Version 3.2018. (2019) (154)
- A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy (2014) (153)
- Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. (2020) (144)
- Myeloid growth factors. (2013) (141)
- Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer (2021) (140)
- In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. (2015) (139)
- LBA13Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086 (2017) (137)
- Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer. (2010) (137)
- Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. (2017) (136)
- Special report: Consensus conference III. Image-detected breast cancer: state-of-the-art diagnosis and treatment. (2009) (136)
- Adjuvant Abemaciclib Combined With Endocrine Therapy for High-Risk Early Breast Cancer: Updated Efficacy and Ki-67 Analysis From the monarchE Study. (2021) (135)
- KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. (2020) (129)
- Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A. (2017) (127)
- Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer (2017) (126)
- PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression (2016) (125)
- Quantitative and clinical description of postural instability in women with breast cancer treated with taxane chemotherapy. (2007) (125)
- NCCN Guidelines Insights: Antiemesis, Version 2.2017. (2017) (123)
- Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)–Positive Metastatic Breast Cancer: A Randomized Clinical Trial (2017) (123)
- Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study (2021) (117)
- Senior adult oncology, version 2.2014: clinical practice guidelines in oncology . (2014) (116)
- Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study (2012) (116)
- A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer (2008) (115)
- Acupressure for chemotherapy-induced nausea and vomiting: a randomized clinical trial. (2007) (114)
- Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial (2017) (114)
- Clinical and biomarker predictors of side effects from tamoxifen (2012) (113)
- NCCN Guidelines® Insights: Breast Cancer, Version 4.2021. (2021) (111)
- Bevacizumab in the treatment of breast cancer: rationale and current data. (2004) (110)
- Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. (2021) (108)
- Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. (2022) (106)
- PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC). (2016) (105)
- Impact of Exploratory Biomarkers on the Treatment Effect of Bevacizumab in Metastatic Breast Cancer (2011) (105)
- Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. (2017) (103)
- Antiemesis. Clinical Practice Guidelines in Oncology. (2004) (102)
- Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer (2014) (102)
- Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. (2013) (101)
- Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2 (2014) (101)
- Abstract S5-07: Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1–positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028 (2016) (99)
- Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial (2012) (98)
- Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients. (2013) (98)
- An Overview of PARP Inhibitors for the Treatment of Breast Cancer (2021) (98)
- Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial (2018) (97)
- Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer (2019) (97)
- Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). (2016) (96)
- Pembrolizumab (pembro) for advanced biliary adenocarcinoma: Results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies. (2019) (95)
- Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130 (2019) (95)
- Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. (2011) (95)
- Cancer-related fatigue. Clinical practice guidelines in oncology. (2003) (93)
- Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. (2020) (93)
- Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer (2007) (92)
- Health‐related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO‐2 trial (2013) (92)
- Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience. (2015) (92)
- Patient perceptions of reproductive health counseling at the time of cancer diagnosis: a qualitative study of female California cancer survivors (2012) (92)
- Antiemesis, version 2.2017 featured updates to the NCCN guidelines (2017) (92)
- A Phase 2 Trial of Dasatinib in Patients with Advanced HER2-Positive and/or Hormone Receptor–Positive Breast Cancer (2011) (92)
- A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO) (2018) (91)
- Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials (2017) (88)
- 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) (2016) (88)
- Associations between pro- and anti-inflammatory cytokine genes and breast pain in women prior to breast cancer surgery. (2012) (87)
- NCCN Clinical Practice Guidelines Cancer-related fatigue. (2010) (85)
- Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. (2020) (85)
- Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2. (2013) (85)
- Time to adjuvant chemotherapy for breast cancer in National Comprehensive Cancer Network institutions. (2013) (85)
- Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. (2021) (84)
- A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. (2014) (84)
- High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. (1997) (84)
- The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer (2015) (82)
- Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data. (2016) (82)
- Biomarker Analyses in the Phase 3 ASCENT Study of Sacituzumab Govitecan Versus Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer. (2021) (80)
- Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer. (2023) (80)
- MONARCH1: Results from a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease. (2016) (80)
- Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC) (2005) (77)
- Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase III SOLAR-1 trial. (2018) (77)
- Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial (2021) (76)
- Everolimus plus exemestane as first-line therapy in HR+, HER2− advanced breast cancer in BOLERO-2 (2013) (75)
- A clinician's guide to biosimilars in oncology. (2016) (75)
- The Modified Total Neuropathy Score: A Clinically Feasible and Valid Measure of Taxane-Induced Peripheral Neuropathy in Women With Breast Cancer (2006) (75)
- Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer (2020) (74)
- ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). (2014) (73)
- A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer (2012) (73)
- The impact of adjuvant therapy for breast cancer on cognitive function: current evidence and directions for research. (2003) (72)
- SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx). (2019) (71)
- Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. (2021) (71)
- Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial. (2015) (70)
- Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival (2008) (69)
- The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors. (2008) (68)
- Studying cancer-related fatigue: report of the NCCN scientific research committee. (2010) (68)
- Biomarker analyses from the phase 3 PALOMA-2 trial of palbociclib (P) with letrozole (L) compared with placebo (PLB) plus L in postmenopausal women with ER + /HER2– advanced breast cancer (ABC) (2016) (67)
- IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC). (2019) (67)
- Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy (2016) (65)
- NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020. (2020) (65)
- Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial. (2012) (64)
- Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors (2019) (63)
- PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel–Treated Advanced Triple-Negative Breast Cancer (2021) (62)
- Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2–Negative Advanced Breast Cancer That Progressed during or after Bevacizumab (2013) (62)
- The cardiac safety of trastuzumab in the treatment of breast cancer (2010) (62)
- Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. (2016) (61)
- Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer (2014) (61)
- DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial (2017) (61)
- Chemotherapy-related amenorrhea after adjuvant paclitaxel–trastuzumab (APT trial) (2015) (59)
- Triple-Negative Breast Cancer: Role of Antiangiogenic Agents (2010) (59)
- Autologous stem cell transplantation for acute myeloid leukemia in first remission. (2000) (59)
- Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. (2022) (59)
- NCCN Guidelines Insights: Older Adult Oncology, Version 2.2016. (2016) (58)
- Final results of a phase 2 study of talazoparib (TALA) following platinum or multiple cytotoxic regimens in advanced breast cancer patients (pts) with germline BRCA1/2 mutations (ABRAZO). (2017) (58)
- A randomized trial of high- vs standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia (1997) (58)
- Implementing decision and communication aids to facilitate patient-centered care in breast cancer: a case study. (2009) (57)
- A prospective analysis of surgery and survival in stage IV breast cancer (TBCRC 013). (2016) (57)
- A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer (2009) (57)
- Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical Trial. (2020) (56)
- Scalp cooling with adjuvant/neoadjuvant chemotherapy for breast cancer and the risk of scalp metastases: systematic review and meta-analysis (2017) (56)
- First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER. (2013) (56)
- Accuracy of selective sentinel lymphadenectomy after neoadjuvant chemotherapy: effect of clinical node status at presentation. (2004) (55)
- Scalp Hypothermia for Preventing Alopecia During Chemotherapy. A Systematic Review and Meta‐Analysis of Randomized Controlled Trials (2017) (55)
- The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression. (2012) (55)
- Senior adult oncology. (2012) (55)
- Older adult oncology, version 2.2016: Featured updates to the NCCN guidelines (2016) (55)
- Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study. (2013) (54)
- Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study (2011) (54)
- Pembrolizumab in patients with advanced cervical squamous cell cancer: Preliminary results from the phase Ib KEYNOTE-028 study. (2016) (53)
- Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice (2016) (53)
- Ixabepilone plus capecitabine vs capecitabine in patients with triple negative tumors: a pooled analysis of patients from two large phase III clinical studies. (2009) (53)
- Breast Cancer, Version 3.2022 (2022) (52)
- 427OPembrolizumab for patients with PD-L1–positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study (2017) (52)
- Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response (2015) (52)
- Patient and physician attitudes toward breast cancer clinical trials: developing interventions based on understanding barriers. (2005) (51)
- Time Course and Management of Key Adverse Events During the Randomized Phase 3 SOLAR-1 Study of PI3K Inhibitor Alpelisib Plus Fulvestrant in Patients With HR-Positive Advanced Breast Cancer. (2020) (51)
- A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer (2011) (50)
- MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial. (2019) (50)
- Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial (2014) (49)
- Correlation of molecular alterations with efficacy of everolimus in hormone receptor–positive, HER2-negative advanced breast cancer: Results from BOLERO-2. (2013) (49)
- The Promise for Histone Methyltransferase Inhibitors for Epigenetic Therapy in Clinical Oncology: A Narrative Review (2020) (49)
- Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER (2014) (48)
- TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer (2015) (48)
- Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer (2018) (48)
- Detection of cerebrospinal fluid tumor cells and its clinical relevance in leptomeningeal metastasis of breast cancer (2015) (48)
- Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer. (2010) (46)
- Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis (2014) (46)
- Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies. (2018) (46)
- Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen (1993) (45)
- Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC). (2017) (45)
- Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs (2018) (45)
- Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Update (2021) (45)
- Quantitative Whole Genome Sequencing of Circulating Tumor Cells Enables Personalized Combination Therapy of Metastatic Cancer. (2017) (44)
- Amelioration of sexual adverse effects in the early breast cancer patient (2010) (44)
- Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer (2014) (43)
- The role of endoscopic evaluation in patients with suspected intestinal graft-versus-host disease after allogeneic bone-marrow transplantation. (1996) (42)
- Fertility preservation with ovarian stimulation and time to treatment in women with stage II–III breast cancer receiving neoadjuvant therapy (2017) (42)
- Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice (2021) (42)
- Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) + aromatase inhibitor (AI): BYL (2020) (42)
- A randomized, double-blind phase II study of the oral tyrosine kinase inhibitor (TKI) axitinib (AG-013736) in combination with docetaxel (DOC) compared to DOC plus placebo (PL) in metastatic breast cancer (MBC) (2007) (42)
- Management of Abemaciclib‐Associated Adverse Events in Patients with Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3 (2020) (41)
- Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial (2021) (41)
- Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen. (1993) (41)
- A Phase II Study of Trastuzumab-DM1 (T-DM1), a Novel HER2 Antibody–Drug Conjugate, in HER2+ Metastatic Breast Cancer (MBC) Patients Previously Treated with Conventional Chemotherapy, Lapatinib and Trastuzumab. (2009) (40)
- Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: diarrheal toxicity in the CONTROL trial. (2020) (40)
- Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer (2013) (39)
- Updated efficacy, safety, & PD-L1 status of patients with HR+, HER2- metastatic breast cancer administered abemaciclib plus pembrolizumab. (2018) (39)
- Human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic options (2015) (39)
- New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer (2009) (38)
- Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial. (2019) (38)
- Correlation of molecular alterations with efficacy of everolimus in hormone receptor-positive, HER2-negative advanced breast cancer: Results from BOLERO-2. (2013) (38)
- Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase 3 trial. (2022) (38)
- TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer. (2020) (37)
- The importance of distant metastases in hormone-sensitive breast cancer. (2008) (37)
- The role of targeted therapy and biomarkers in breast cancer treatment (2012) (37)
- The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea (2019) (36)
- NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron (2016) (36)
- SIS.NET: A randomized controlled trial evaluating a web‐based system for symptom management after treatment of breast cancer (2015) (35)
- Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial (2017) (35)
- Phase II trial of erlotinib (OSI-774), an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, and bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial growth factor (VEGF), in patients (pts) with metastatic breast cancer (MBC). (2004) (35)
- MYC Dysregulates Mitosis, Revealing Cancer Vulnerabilities. (2020) (35)
- Inhibiting angiogenesis in breast cancer: the beginning of the end or the end of the beginning? (2012) (34)
- Which factors should be taken into account in perimenopausal women with early breast cancer who may become eligible for an aromatase inhibitor? Recommendations of an expert panel. (2011) (34)
- Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03) (2021) (34)
- Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers (2014) (34)
- Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic. (2020) (33)
- Immunotherapy for early triple negative breast cancer: research agenda for the next decade (2022) (33)
- Management of breast cancer diagnosed during pregnancy (2003) (33)
- Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2− Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA‐2 Trial (2019) (33)
- The Role of Trastuzumab in Early Stage Breast Cancer: Current Data and Treatment Recommendations (2007) (33)
- Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): Updated analyses from PALOMA-3. (2021) (33)
- A multicenter, open-label phase II trial of dovitinib, an FGFR1 inhibitor, in FGFR1 amplified and non-amplified metastatic breast cancer. (2011) (32)
- TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple-negative breast cancer and evaluation of p63/p73 as a biomarker of response. (2011) (32)
- NCCN Guidelines® Insights: Breast Cancer, Version 4.2021. (2021) (32)
- Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance) (2018) (32)
- A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation (2018) (32)
- Phase 3 study evaluating efficacy and safety of veliparib (V) plus carboplatin (Cb) or Cb in combination with standard neoadjuvant chemotherapy (NAC) in patients (pts) with early stage triple-negative breast cancer (TNBC). (2017) (30)
- Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer. (2020) (30)
- Abstract GS1-02: Phase 3 SOPHIA study of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies: second interim overall survival analysis (2020) (30)
- A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies (2016) (29)
- An open‐label, phase 2 trial of RPI.4610 (angiozyme) in the treatment of metastatic breast cancer (2012) (29)
- The efficacy, challenges, and facilitators of telemedicine in post-treatment cancer survivorship care: an overview of systematic reviews. (2021) (29)
- Dasatinib in advanced HER2/neu amplified and ER/PR-positive breast cancer: Phase II study CA180088. (2016) (29)
- Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology (2021) (29)
- Pembrolizumab in advanced endometrial cancer: Preliminary results from the phase Ib KEYNOTE-028 study. (2016) (28)
- A Feasibility Study of Bevacizumab plus Dose-Dense Doxorubicin–Cyclophosphamide (AC) Followed by Nanoparticle Albumin–Bound Paclitaxel in Early-Stage Breast Cancer (2011) (28)
- Oncological care organisation during COVID-19 outbreak (2020) (28)
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer (2021) (28)
- Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer. (2014) (28)
- Letrozole (L) with bevacizumab (B) is feasible in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC). (2006) (27)
- Informational Needs of Patients with Metastatic Breast Cancer: What Questions Do They Ask, and Are Physicians Answering Them? (2014) (27)
- Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer (2018) (27)
- Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer (2012) (27)
- Impact of bevacizumab (BEV) on efficacy of second-line chemotherapy (CT) for triple-negative breast cancer (TNBC): Analysis of RIBBON-2. (2011) (27)
- Response of Brain Metastases From PIK3CA-Mutant Breast Cancer to Alpelisib (2020) (26)
- The tumor microenvironment (TME) and atezolizumab + nab-paclitaxel (A+nP) activity in metastatic triple-negative breast cancer (mTNBC): IMpassion130. (2021) (26)
- Bevacizumab for advanced breast cancer. (2007) (26)
- Abstract GS1-05: TBCRC 033: A randomized phase II study of adjuvant trastuzumab emtansine (T-DM1) vs paclitaxel (T) in combination with trastuzumab (H) for stage I HER2-positive breast cancer (BC) (ATEMPT) (2020) (26)
- Reducing the long-term effects of chemotherapy in young women with early-stage breast cancer. (2011) (26)
- Trop2 gene expression (Trop2e) in primary breast cancer (BC): Correlations with clinical and tumor characteristics. (2017) (26)
- Improving Response to Hormone Therapy in Breast Cancer: New Targets, New Therapeutic Options. (2016) (26)
- Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study (2020) (25)
- Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. (2014) (25)
- Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction. (2009) (25)
- The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer (2014) (25)
- Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2− Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1) (2021) (25)
- Dosing and Safety Implications for Oncologists When Administering Everolimus to Patients With Hormone Receptor-Positive Breast Cancer. (2016) (25)
- Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial. (2021) (24)
- A Novel Strategy for Detection and Enumeration of Circulating Rare Cell Populations in Metastatic Cancer Patients Using Automated Microfluidic Filtration and Multiplex Immunoassay (2015) (24)
- A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer (2013) (24)
- Improved clinical and cell cycle response with an mTOR inhibitor, daily oral RAD001 (everolimus) plus letrozole versus placebo plus letrozole in a randomized phase II neoadjuvant trial in ER+ breast cancer (2008) (24)
- Reversing hormone resistance: have we found the golden key? (2012) (24)
- Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician’s Choice Standard-of-Care Chemotherapy (2019) (24)
- Targeting growth factors and angiogenesis; using small molecules in malignancy (2006) (23)
- Local–regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial) (2019) (23)
- IMpassion130: a Phase III randomized trial of atezolizumab with nab-paclitaxel for first-line treatment of patients with metastatic triple-negative breast cancer (mTNBC). (2016) (23)
- Randomized phase II/III trial of active immunotherapy with OPT-822/OPT-821 in patients with metastatic breast cancer. (2016) (23)
- Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial. (2021) (23)
- A phase Ib study of abemaciclib in combination with pembrolizumab for patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer (MBC) (NCT02779751): Interim results. (2020) (23)
- Endocrine Therapy for Hormone Receptor Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline Summary. (2016) (23)
- Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. (2022) (22)
- Change in circulating endothelial cells (CEC) and tumor cells (CTC) in patients (pts) receiving bevacizumab and erlotinib for metastatic breast cancer (MBC) predicts stable disease at first evaluation (2005) (22)
- Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer (2022) (22)
- De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry. (2020) (22)
- Efficacy and Safety of Ixabepilone and Capecitabine in Patients With Advanced Triple‐negative Breast Cancer: a Pooled Analysis From Two Large Phase III, Randomized Clinical Trials (2018) (22)
- Effect of trastuzumab on health-related quality of life in patients with HER2-positive metastatic breast cancer: data from three clinical trials. (2010) (22)
- Developing Safety Criteria for Introducing New Agents into Neoadjuvant Trials (2013) (22)
- 2103 ORAL A randomized, double-blind phase 2 study of the oral tyrosine kinase inhibitor (TKI) axitinib (AG-013736; AG) in combination with docetaxel (DOC) vs DOC plus placebo (PL) in first-line metastatic breast cancer (MBC) (2007) (21)
- Targeting the androgen receptor (AR) in women with AR+ ER-/PR- metastatic breast cancer (MBC). (2012) (21)
- Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial (2021) (21)
- Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2. (2019) (21)
- Progress against solid tumors in danger: the metastatic breast cancer example. (2012) (21)
- Registry study to assess hair loss prevention with the Penguin Cold Cap in breast cancer patients receiving chemotherapy (2017) (20)
- Prognostic associations of 25 hydroxy vitamin D in NCIC CTG MA.21, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in high-risk breast cancer (2015) (20)
- Health-related quality of life and disease symptoms in postmenopausal women with HR+, HER2− advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy (2013) (20)
- Cancer-Related FatiguePractice Guidelines in Oncology (2010) (20)
- Emerging treatments in chemotherapy-induced nausea and vomiting. (2013) (20)
- Change in Topoisomerase 1–Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol (2018) (20)
- The role of angiogenesis inhibition in the treatment of breast cancer. (2006) (20)
- Genomic and expression profiling reveal molecular heterogeneity of disseminated tumor cells in bone marrow of early breast cancer (2018) (20)
- A Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and Vomiting (2015) (19)
- Trends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers (2016) (19)
- Oncologist use of the Adjuvant! model for risk communication: a pilot study examining patient knowledge of 10-year prognosis (2009) (19)
- Genome-Wide Meta-Analysis Validates a Roless for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy. (2020) (19)
- Antiangiogenic and Antitumor Effects of Bevacizumab in Patients With Inflammatory and Locally Advanced Breast Cancer (2007) (18)
- The impact of an electronic health questionnaire on symptom management and behavior reporting for breast cancer survivors (2012) (18)
- Corrigendum to "3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)" [Breast 31 (February 2017) 244-259]. (2017) (18)
- Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies (2020) (18)
- Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results from the KEYNOTE-028 Study (2018) (18)
- Abstract PD1-07: Exploratory analytical harmonization of PD-L1 immunohistochemistry assays in advanced triple-negative breast cancer: A retrospective substudy of IMpassion130 (2020) (18)
- Demystifying biosimilars: development, regulation and clinical use. (2019) (18)
- Adjuvant Abemaciclib Combined with Endocrine Therapy for High Risk Early Breast Cancer: Safety and Patient-Reported Outcomes From the monarchE Study. (2022) (18)
- Abstract PD5-5: Phase I study of the PI3Kα inhibitor BYL719 plus fulvestrant in patients withPIK3CA-altered and wild type ER+/HER2- locally advanced or metastatic breast cancer (2015) (18)
- Sacituzumab Govitecan For Metastatic Triple Negative Breast Cancer: Clinical Overview And Management Of Potential Toxicities. (2021) (17)
- Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer From SOLAR-1 (2021) (17)
- Fitbit Usage in Patients With Breast Cancer Undergoing Chemotherapy. (2019) (17)
- Post-remission cytopenias following intense induction chemotherapy for acute myeloid leukemia. (1994) (17)
- Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657) (2017) (17)
- The value of embedding: integrated palliative care for patients with metastatic breast cancer (2018) (17)
- Role of Fcγ receptors in HER2-targeted breast cancer therapy (2022) (17)
- SOLAR-1: A phase III study of alpelisib + fulvestrant in men and postmenopausal women with HR+/HER2– advanced breast cancer (BC) progressing on or after prior aromatase inhibitor therapy. (2016) (17)
- Phase II trial of the histone deacetylase inhibitor, vorinostat, to restore hormone sensitivity to the antiestrogen tamoxifen in patients with advanced breast cancer who progressed on prior hormone therapy. (2016) (17)
- Phase III trial evaluating the addition of bevacizumab to letrozole as first-line endocrine therapy for treatment of hormone-receptor positive advanced breast cancer: CALGB 40503 (Alliance). (2015) (17)
- Erratum to: Fertility preservation with ovarian stimulation and time to treatment in women with stage II–III breast cancer receiving neoadjuvant therapy (2017) (16)
- Abstract CT011: Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL (2020) (16)
- The evolution of cyclin dependent kinase inhibitors in the treatment of cancer (2021) (16)
- Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study (2022) (16)
- A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). (2015) (16)
- Abstract GS1-02: Phase III study of palbociclib combined with endocrine therapy (ET) in patients with hormone-receptor-positive (HR+), HER2-negative primary breast cancerand with high relapse risk after neoadjuvant chemotherapy (NACT): First results from PENELOPE-B (2021) (16)
- Clinical and dynamic imaging results of the first phase I study of AG-013736, an oral anti-angiogenesis agent, in patients (pts) with advanced solid tumors (2004) (16)
- Zoledronic acid (ZA) as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells (DTC) in bone marrow (BM) (2008) (16)
- Abemaciclib for pre/perimenopausal women with HR+, HER2- advanced breast cancer. (2018) (16)
- Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs (2019) (15)
- Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, correlates with the degree of AR positivity in advanced AR+/estrogen receptor (ER)+ breast cancer in an international phase 2 clinical study. (2021) (15)
- Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development. (2012) (15)
- Challenging clinical scenarios: treatment of patients with triple-negative or basal-like metastatic breast cancer. (2010) (15)
- Long‐Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor‐Positive/Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow‐Up (2021) (15)
- Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment (2011) (15)
- Identification of biomarkers to predict response to single-agent platinum chemotherapy in metastatic triple-negative breast cancer (mTNBC): Correlative studies from TBCRC009. (2014) (15)
- Combined peripheral natural killer cell and circulating tumor cell enumeration enhance prognostic efficiency in patients with metastatic triple-negative breast cancer. (2018) (15)
- Abstract PD13-07: Subgroup analysis of patients with brain metastases from the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in metastatic triple-negative breast cancer (2021) (15)
- A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer (2017) (15)
- Practice patterns in the delivery of radiation therapy after mastectomy among the University of California Athena Breast Health Network. (2015) (15)
- Heritage: A phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus Herceptin. (2016) (15)
- Stomatitis associated with mammalian target of rapamycin inhibition: A review of pathogenesis, prevention, treatment, and clinical implications for oral practice in metastatic breast cancer. (2018) (14)
- Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with pembrolizumab in patients with advanced/metastatic breast or non-small cell lung cancer (NSCLC): A phase Ib, multicenter, study. (2020) (14)
- Phase II study of irinotecan and temozolomide in breast cancer patients with progressing central nervous system disease (2019) (14)
- Serial analysis of circulating tumor cells in metastatic breast cancer receiving first-line chemotherapy. (2020) (14)
- Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim. (2006) (14)
- A phase II study of medroxyprogesterone acetate in patients with hormone receptor negative metastatic breast cancer: translational breast cancer research consortium trial 007 (2010) (14)
- A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel (2019) (14)
- Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors (2020) (14)
- Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars (2020) (14)
- Everolimus and its role in hormone-resistant and trastuzumab-resistant metastatic breast cancer. (2012) (14)
- Comparative effectiveness analysis of monotherapy with cytotoxic agents in triple-negative metastatic breast cancer in a community setting. (2015) (14)
- Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer (2015) (13)
- Tyrosine Kinase Inhibitors for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Is Personalizing Therapy Within Reach? (2017) (13)
- Risk communication with patients with breast cancer: cautionary notes about printing Adjuvant! estimates. (2008) (13)
- Novel taxane formulations in the treatment of breast cancer: a thought leader discussion and consensus roundtable. (2008) (13)
- A Pharmacogenetic Prediction Model of Progression‐Free Survival in Breast Cancer using Genome‐Wide Genotyping Data from CALGB 40502 (Alliance) (2018) (13)
- Fixed combination of oral NEPA (netupitant‐palonosetron) for the prevention of acute and delayed chemotherapy‐induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double‐blind phase III studies (2019) (13)
- Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor-2-negative (HER2-) advanced breast cancer (ABC): First interim BYLieve study results. (2019) (13)
- 296P Tumour mutational burden and clinical outcomes with first-line atezolizumab and nab-paclitaxel in triple-negative breast cancer: Exploratory analysis of the phase III IMpassion130 trial (2020) (13)
- Abstract LB-225: RNA molecular signatures as predictive biomarkers of response to monotherapy pembrolizumab in patients with metastatic triple-negative breast cancer: KEYNOTE-086 (2019) (13)
- A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer (2017) (13)
- Improving Response to Hormone Therapy in Breast Cancer: New Targets, New Therapeutic Options. (2016) (13)
- High-dose chemotherapy (CTM) for breast cancer (2000) (13)
- Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials (2020) (13)
- Effectiveness of Alpelisib + Fulvestrant Compared with Real‐World Standard Treatment Among Patients with HR+, HER2–, PIK3CA‐Mutated Breast Cancer (2021) (13)
- Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. (2022) (13)
- Effect of prophylaxis on neratinib-associated diarrhea and tolerability in patients with HER2+ early-stage breast cancer: Phase II CONTROL trial. (2019) (13)
- NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022. (2022) (12)
- Cancer-Related Fatigue , Version 2 . 2015 Clinical Practice Guidelines in Oncology (2015) (12)
- De Novo Versus Recurrent HER2‐Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry (2019) (12)
- Nimbus: A phase II study of nivolumab plus ipilimumab in metastatic hypermutated HER2-negative breast cancer. (2019) (12)
- Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer (2022) (12)
- Concordance between the 21-gene recurrence score (RS) and the 70-gene profile (MP) in breast cancer (BC) patients (pts). (2011) (12)
- Androgen receptor gene expression in primary breast cancer (2019) (12)
- ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases. (2019) (12)
- Achieving Improved Survival Outcomes in Advanced Breast Cancer. (2019) (12)
- A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer. (2019) (11)
- Navigating a Path to Equity in Cancer Care: The Role of Patient Navigation. (2021) (11)
- Abstract GS3-01: Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer (2021) (11)
- Talazoparib in Patients with a Germline BRCA‐Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial (2019) (11)
- Phase 3 study of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting during repeated moderately emetogenic chemotherapy (MEC) cycles. (2014) (11)
- 451PDPHASE I STUDY OF THE PI3Kα INHIBITOR BYL719, AS A SINGLE AGENT IN PATIENTS WITH ADVANCED SOLID TUMORS (AST). (2014) (11)
- 42O_PRASSESSMENT OF GENETIC ALTERATIONS IN POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER FROM THE BOLERO-2 TRIAL BY NEXT-GENERATION SEQUENCING (2013) (11)
- HERITAGE: a phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus herceptin (2017) (11)
- Survival of patients with HER2+ metastatic breast cancer and use of trastuzumab following progression: analysis of RegistHER. (2009) (11)
- Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial. (2017) (11)
- SPARC microenvironment signature (SMS) analysis of a phase II trial of neoadjuvant gemcitabine (G), epirubicin (E), and nab-paclitaxel (nab-P) in locally advanced breast cancer (LABC). (2010) (10)
- Abstract P4-10-04: Clinical outcomes of alpelisib in hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer by next-generation sequencing-detected PIK3CA alteration status and phosphatase and tensin homolog loss: Biomarker analysis from the SOLAR-1 study (2020) (10)
- Busulfan plus etoposide as a preparative regimen for autologous bone marrow transplantation for acute myelogenous leukemia: an update. (1993) (10)
- Palbociclib (PAL) + letrozole (L) as first-line (1L) therapy (tx) in estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): Efficacy and safety across patient (pt) subgroups. (2017) (10)
- Plasma PIK3CA ctDNA specific mutation detected by next generation sequencing is associated with clinical outcome in advanced breast cancer. (2018) (10)
- registHER: A prospective, longitudinal cohort study of women with HER2 positive metastatic breast cancer (2005) (10)
- Hormone therapy in premenopausal women with early-stage breast cancer. (2014) (10)
- Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG). (2020) (10)
- Analysis of germline BRCA1/2 mutated (gBRCAmut) hormone receptor-positive (HR+) and triple negative breast cancer (TNBC) treated with talazoparib (TALA). (2018) (10)
- Prognostic Factors for Overall Survival in Patients with Hormone Receptor‐Positive Advanced Breast Cancer: Analyses From PALOMA‐3 (2021) (10)
- Abstract OT1-01-06: A phase III randomized trial of atezolizumab in combination with nab-paclitaxel as first line therapy for patients with metastatic triple-negative breast cancer (mTNBC) (2016) (10)
- Abstract PD5-1: Results from the phase 2 trial of ridaforolimus, dalotuzumab, and exemestane compared to ridaforolimus and exemestane in advanced breast cancer (2015) (10)
- Abstract PD1-10: Evaluation of SGN-LIV1a followed by AC in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL (2021) (10)
- The impact of 5-hydroxytryptamine-receptor antagonists on chemotherapy treatment adherence, treatment delay, and nausea and vomiting (2015) (10)
- The association of early toxicity and outcomes for patients treated with abemaciclib. (2018) (10)
- Abstract CT106: Efficacy of pertuzumab/trastuzumab/paclitaxel over standard trastuzumab/paclitaxel therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL (2016) (10)
- Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial. (2022) (9)
- The DigniCap Scalp Cooling System and its use in the treatment of chemotherapy-induced alopecia. (2018) (9)
- KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) plus olaparib vs pembro plus chemotherapy after induction with first-line pembro plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC). (2020) (9)
- P1.01A phase 3 study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with advanced breast cancer (EMBRACA) (2015) (9)
- Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial (2021) (9)
- Final overall survival (OS) and safety analyses of RIBBON-2, a randomized phase III trial of bevacizumab (BEV) versus placebo (PL) combined with second-line chemotherapy (CT) for HER2-negative BEV-naive metastatic breast cancer (MBC). (2012) (9)
- Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance) (2018) (9)
- Abstract CT142: Prevalence ofPIK3CAmutations in patients with hormone receptor-positive, human epidermal growth factor-2-negative advanced breast cancer from the SOLAR-1 trial (2019) (9)
- Targeting the host immune system: PD-1 and PD-L1 antibodies and breast cancer (2016) (9)
- Clinical performance of the DigniCap system, a scalp hypothermia system, in preventing chemotherapy-induced alopecia. (2015) (9)
- Most neoadjuvant chemotherapy for triple-negative breast cancer should include platinum. (2021) (9)
- Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial) (2021) (9)
- Efficacy of NEPA (netupitant/palonosetron) across multiple cycles of chemotherapy in breast cancer patients: A subanalysis from two phase III trials. (2017) (9)
- Cost Comparison of Capecitabine in Patients With Breast Cancer (2010) (9)
- A phase 1b study to assess the safety of PLX3397, a CSF-1 receptor inhibitor, and paclitaxel in patients with advanced solid tumors. (2014) (9)
- New and emerging therapeutic options for the management of chemotherapy-induced nausea and vomiting. (2015) (9)
- Androgen receptor gene expression in primary breast cancer (2019) (9)
- Study CTKI258A2202: A multicenter, open-label phase II trial of dovitinib (TKI258) in FGFR1-amplified and nonamplified HER2-negative metastatic breast cancer. (2010) (9)
- Breast cancer, locally advanced and metastatic (2012) (9)
- 350TiP A phase III trial of capivasertib and fulvestrant versus placebo and fulvestrant in patients with HR+/HER2− breast cancer (CAPItello-291) (2020) (9)
- Breast cancer, locally advanced and metastatic (2012) (9)
- Impact of palbociclib plus letrozole on health related quality of life (HRQOL) compared with letrozole alone in treatment naïve postmenopausal patients with ER+ HER2- metastatic breast cancer (MBC): results from PALOMA-2 (2016) (9)
- Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG) (2018) (9)
- Clinical Significance of Circulating Tumor Cells in Hormone Receptor–positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab (2020) (8)
- Systemic treatment of early breast cancer—a biological perspective (2011) (8)
- Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi‐institutional study (2015) (8)
- Integrating outpatient palliative care into a metastatic breast oncology clinic. (2015) (8)
- A Phase II Study of Vaginal Testosterone Cream (TEST) vs. Estring for Vaginal Dryness or Decreased Libido in Women with Early Stage Breast Cancer (BC) Treated with Aromatase Inhibitors (AIs). (2009) (8)
- Strategies for the prevention of treatment-related bone loss in women receiving adjuvant hormonal therapy. (2007) (8)
- P120 Adjuvant therapies: distant disease-free survival as a predictor of overall survival (2007) (8)
- Planning for post‐pandemic cancer care delivery: Recovery or opportunity for redesign? (2020) (8)
- Phase Ib study of gedatolisib in combination with palbociclib and endocrine therapy (ET) in women with estrogen receptor (ER) positive (+) metastatic breast cancer (MBC) (B2151009). (2018) (8)
- Abstract P1-19-02: Overall survival for first-line palbociclib plus letrozole vs letrozole alone for HR+/HER2- metastatic breast cancer patients in US real-world clinical practice (2020) (8)
- A phase 3 study of alpelisib (ALP) plus fulvestrant (FUL) in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) ABC progressing on or after aromatase inhibitor (AI) therapy: SOLAR-1. (2017) (8)
- Neoplasms of the Breast (2017) (8)
- Evaluation of intra-tumoral (IT) SD-101 and pembrolizumab (Pb) in combination with paclitaxel (P) followed by AC in high-risk HER2-negative (HER2-) stage II/III breast cancer: Results from the I-SPY 2 trial. (2021) (8)
- A feasibility study of an aromatase inhibitor (AI), letrozole (L) and the antibody to vascular endothelial growth factor (VEGF), bevacizumab (B), in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC) (2005) (8)
- Clinical roundtable monograph: New data in emerging treatment options for chemotherapy-induced nausea and vomiting. (2014) (8)
- The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer (2021) (8)
- A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma. (2019) (8)
- Incidence, management, and resolution of noninfectious pneumonitis in BOLERO-2. (2013) (8)
- Abstract CT044: MONARCH 1: Final overall survival analysis of a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease (2017) (8)
- Abstract P3-07-14: Increasing proportion of de novo compared with recurrent HER2-positive metastatic breast cancer: Early results from the systemic therapies for HER2-positive metastatic breast cancer registry study (2015) (8)
- Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer (2021) (8)
- Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis (2022) (7)
- 291PPALOMA-2: Neutropenia (NP) patterns in patients (Pts) with estrogen receptor−positive (ER+)/human epidermal growth factor receptor 2−negative (HER2–) first-line advanced breast cancer (ABC) receiving palbociclib + letrozole (P+L) (2017) (7)
- Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid (2021) (7)
- Phase III study evaluating safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy in subjects with early-stage triple-negative breast cancer (TNBC). (2014) (7)
- Effects of everolimus (EVE) on disease progression in bone and bone markers (BMs) in patients (pts) with bone metastases (mets). (2012) (7)
- Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer (2021) (7)
- Emerging treatment strategies for metastatic triple-negative breast cancer (2022) (7)
- A pilot study of adjuvant bevacizumab and chemotherapy after neoadjuvant chemotherapy for high-risk breast cancer (2008) (7)
- New developments in metastatic breast cancer: integrating recent data into clinical practice. (2013) (7)
- Clinical Phase II Study of Vorinostat, a Hydroxamic Type Histone Deacetylase Inhibitor, in Combination with Tamoxifen To Reverse Acquired Hormone Resistance in Breast Cancer Patients Who Progressed on Hormone Therapy. (2009) (7)
- Synchronous Breast Implant–associated Anaplastic Large Cell Lymphoma and Invasive Carcinoma: Genomic Profiling and Management Implications (2019) (7)
- TBCRC 011: Targeting the androgen receptor (AR) for the treatment of AR+/ER-/PR- metastatic breast cancer (MBC). (2011) (7)
- Advance Care Planning in Community: An Evaluation of a Pilot 2-Session, Nurse-Led Workshop (2018) (7)
- Abstract 4564: Assessment of genetic alterations using next-generation sequencing in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the BOLERO-2 phase III trial. (2013) (7)
- Harmonizing PD-L1 testing in metastatic triple negative breast cancer (2021) (7)
- Biosimilar trastuzumab-dkst monotherapy versus trastuzumab monotherapy after combination therapy: Final overall survival (OS) from the phase III HERITAGE Trial. (2019) (7)
- Predictive Biomarkers and Personalized Medicine Targeting FGFR with Dovitinib ( TKI 258 ) : Preclinical and Clinical Data in Breast Cancer (2013) (7)
- A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast cancer (TNBC) and response correlation with MYC-overexpression. (2020) (7)
- Clinical and dynamic imaging results of the first phase I study of AG-013736, an oral anti-angiogenesis agent, in patients (pts) with advanced solid tumors. (2004) (7)
- Abstract PD8-01: Phase 3 SOPHIA study of margetuximab (M) + chemotherapy (CTX) vs trastuzumab (T) + CTX in patients (pts) with HER2+ metastatic breast cancer (MBC) after prior anti-HER2 therapies: Final overall survival (OS) analysis (2022) (7)
- SOPHIA: A phase 3, randomized study of margetuximab (M) plus chemotherapy (CTX) vs trastuzumab (T) plus CTX in the treatment of patients with HER2+ metastatic breast cancer (MBC). (2016) (7)
- Abstract PD14-07: Association between biomarkers and response to pembrolizumab in patients with metastatic triple-negative breast cancer (mTNBC): Exploratory analysis from KEYNOTE-086 (2021) (7)
- Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance) (2017) (7)
- Translating the Molecular Message of Triple-Negative Breast Cancer into Targeted Therapy (2014) (6)
- Abstract CT108: A phase 1b study of abemaciclib in combination with pembrolizumab for patients (pts) with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (mBC) (NCT02779751): Preliminary results (2020) (6)
- LBA76_PR Expected medium and long term impact of the COVID-19 outbreak in oncology (2020) (6)
- RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer (2021) (6)
- Programmed cell death 1 (PD-1) receptor and programmed death ligand 1 (PD-L1) gene expression in primary breast cancer (2021) (6)
- P170 The number needed to treat (NNT) as a measure of drug efficacy: the case of aromatase inhibitors (AIs) in post menopausal women with early breast cancer (2007) (6)
- A pilot study of adjuvant bevacizumab after neoadjuvant chemotherapy for high-risk breast cancer (2007) (6)
- Outcomes in patients (pts) aged ≥65 years in the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC). (2021) (6)
- Treatment of acute leukemia with idarubicin, etoposide and cytarabine (IDEA). A randomized study of etoposide schedule (2004) (6)
- Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3. (2021) (6)
- Abstract CT071: Talazoparib (TALA) in germlineBRCA1/2(gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): Final overall survival (OS) results from randomized Phase 3 EMBRACA trial (2020) (6)
- Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer (2022) (6)
- The Transcription Factor ZNF 217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression (2012) (6)
- A multidisciplinary approach to optimizing care of patients treated with alpelisib (2021) (6)
- Antiangiogenic (AG) Synergy with Ixabepilone (IXA): Translation of Preclinical Studies to the Clinical Setting. (2009) (6)
- Tumor cell-adipocyte gap junctions activate lipolysis and are essential for breast tumorigenesis (2018) (6)
- Proceedings of the First Global Workshop on Breast Cancer: pathways to the evaluation and clinical development of novel agents for breast cancer. (2010) (6)
- Methylome Variation Predicts Exemestane Resistance in Advanced ER+ Breast Cancer (2020) (6)
- Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor‐positive/human epidermal growth factor receptor 2‐negative metastatic breast cancer (2019) (6)
- Time trends in the use of adjuvant chemotherapy (CTX) and outcomes in women with T1N0 breast cancer (BC) in the National Comprehensive Cancer Network (NCCN) (2013) (6)
- Abstract P6-11-12: Subgroup Analysis by prior treatment and disease burden in MONARCH 1: A phase 2 study of monotherapy abemaciclib, a CDK4 & 6 inhibitor, in patients with HR+/HER2 metastatic breast cancer (MBC) following chemotherapy (2017) (6)
- SU11248 (sunitinib malate) therapy in patients with refractory metastatic breast cancer: preliminary safety and efficacy results from a phase II study (2006) (6)
- Temporary amenorrhea predicts future infertility in young women treated with chemotherapy (2013) (6)
- Immunophenotype and proliferation to predict for response to neoadjuvant chemotherapy in TNBC: Results from BrighTNess phase III study. (2019) (6)
- Treatment-related side effects and views about dosage assessment to sustain quality of life: Results of an advocate-led survey of patients with metastatic breast cancer (MBC). (2021) (6)
- Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer. (2021) (6)
- A phase I study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients (pts) with advanced solid tumors. (2017) (6)
- 84PDRelationship of PD-L1 and a T-cell inflamed gene expression profile (GEP) to clinical response in a multicohort trial of solid tumors (KEYNOTE [KN]028) (2017) (6)
- Phase III trial of etirinotecan pegol (EP) versus Treatment of Physician’s Choice (TPC) in patients (pts) with advanced breast cancer (aBC) whose disease has progressed following anthracycline (A), taxane (T) and capecitabine (C): The BEACON study. (2015) (6)
- Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness (2021) (6)
- A Phase II Feasibility Study of Palbociclib in Combination with Adjuvant Endocrine Therapy for Hormone Receptor Positive Invasive Breast Carcinoma. (2019) (6)
- Meta-analysis of stomatitis incidence in everolimus (EVE) clinical studies and its relationship with efficacy. (2014) (6)
- Adjuvant therapy for early stage breast cancer (EBC): Distant disease-free survival (DDFS) as a predictor of overall survival (OS) (2007) (6)
- Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015 (2020) (6)
- Abstract OT1-1-12: A phase 3, open-label, randomized, parallel, 2-arm multi-center study of the oral PARP inhibitor BMN 673 versus physician's choice in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA study) (2015) (6)
- Abstract P2-13-02: Chemotherapy-related amenorrhea (CRA) after adjuvant trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT trial) (2020) (6)
- Patient-reported outcomes (PROs) from the phase III IMpassion130 trial of atezolizumab (atezo) plus nabpaclitaxel (nP) in metastatic triple-negative breast cancer (mTNBC). (2019) (5)
- Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial (2022) (5)
- Abstract GS4-01: Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane (2021) (5)
- Geographic Variation in Postoperative Imaging for Low-Risk Breast Cancer. (2018) (5)
- 447PDPHASE IB STUDY OF PLX3397, A CSF1R INHIBITOR, AND PACLITAXEL IN PATIENTS WITH ADVANCED SOLID TUMORS. (2014) (5)
- A phase II study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor-positive (ER+) breast cancer. (2011) (5)
- Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial (2016) (5)
- Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy (2022) (5)
- Human herpesvirus 8 (KSHV) contamination of peripheral blood and autograft products from multiple myeloma patients (2000) (5)
- Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; 32: 983-993. (2021) (5)
- Impact of hormone receptor (HR) status on clinicopathological features, patterns of recurrence, and clinical outcomes among patients (pts) with human epidermal growth factor receptor-2 positive (HER2) breast cancer (BC) in the National Comprehensive Cancer Network (NCCN). (2012) (5)
- Advocacy spurs innovation: promoting synergy between physical and biomedical sciences (2013) (5)
- Prognostic Value of Plasma HER2 Gene Copy Number in HER2-Positive Metastatic Breast Cancer Treated with First-Line Trastuzumab (2020) (5)
- Abstract P3-09-02: Evaluation of a novel agent plus standard neoadjuvant therapy in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL (2020) (5)
- Optimal Strategies for Successful Initiation of Neratinib in Patients with HER2-Positive Breast Cancer. (2021) (5)
- Phase Ib dose-escalation trial of the AKT inhibitor (AKTi) MK2206 in combination with paclitaxel (P) and trastuzumab (H) in patients (pts) with HER2-overexpressing (HER2+) cancer. (2013) (5)
- A semi-physiologic population pharmacokinetic/pharmacodynamic (PK/PD) model of thrombocytopenia (TCP) characterizing the effect of trastuzumab-DM1 (T-DM1) on platelet counts in patients with HER2-positive MBC. (2011) (5)
- TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer (2020) (5)
- Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: Results from the phase III BrighTNess trial. (2020) (5)
- Histology-agnostic approvals for antibody-drug conjugates in solid tumours: is the time ripe? (2022) (5)
- Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial (2017) (5)
- A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer. (2021) (5)
- 257P Health-related quality of life (HRQoL) in the ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC) (2021) (5)
- High-Dose Etoposide, Thiotepa, and Dose-Adjusted Carboplatin (TVCa) With Autologous Hematopoietic Stem Cell Rescue as Treatment of Relapsed or Refractory Germ Cell Cancer (2005) (5)
- Abstract GS3-06: Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer (2021) (5)
- Clinical roundtable monograph. Current treatment options for metastatic breast cancer: what now? (2011) (5)
- Abstract PD13-05: Alpelisib + fulvestrant in patients with PIK3CA-mutated, HR+, HER2— advanced breast cancer (ABC) who received chemotherapy or endocrine therapy (ET) as immediate prior treatment: BYLieve Cohort C primary results and exploratory biomarker analyses (2022) (4)
- Abstract 2679: Integration of DNA repair deficiency and immune biomarkers to predict which early-stage triple-negative breast cancer patients are likely to respond to platinum-containing regimens vs. immunotherapy: The neoadjuvant I-SPY 2 trial (2019) (4)
- A phase Ib study of pexidartinib (PLX3397) and weekly paclitaxel in patients with advanced solid tumors including an ovarian cancer subset (2016) (4)
- 352TiP EPIK-B2: A phase III study of alpelisib (ALP) as maintenance therapy with trastuzumab (T) and pertuzumab (P) in patients (pts) with PIK3CA-mutated (mut) human epidermal growth factor receptor-2–positive (HER2+) advanced breast cancer (ABC) (2020) (4)
- A 4-Month Whole-Systems Ayurvedic Medicine Nutrition and Lifestyle Intervention Is Feasible and Acceptable for Breast Cancer Survivors: Results of a Single-Arm Pilot Clinical Trial (2020) (4)
- XENERA-1: A phase II trial of xentuzumab (Xe) in combination with everolimus (Ev) and exemestane (Ex) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) and non-visceral involvement. (2019) (4)
- ABT-869 in Combination with Paclitaxel (P) as First-Line Treatment in Patients (Pts) with Advanced Breast Cancer. (2009) (4)
- The (R)evolution of Social Media in Oncology: Engage, Enlighten, and Encourage. (2022) (4)
- Phase I study of sunitinib in combination with metronomic dosing of cyclophosphamide and methotrexate in patients with metastatic breast cancer. (2009) (4)
- Alpelisib (ALP) + fulvestrant (FUL) for patients with hormone receptor–positive (HR+), HER2− advanced breast cancer (ABC): Management and time course of key adverse events of special interest (AESIs) in SOLAR-1 (2019) (4)
- EMBRACA: Efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation. (2018) (4)
- Circulating Tumors Cells as a Biomarker of Radiation Benefit. (2018) (4)
- Abstract CT136: Evaluation of talazoparib in combination with irinotecan in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL (2019) (4)
- Paclitaxel poliglumex. Cell Therapeutics/Chugai Pharmaceutical. (2005) (4)
- Abstract PS11-09: Impact ofUGT1A1status on the safety profile of sacituzumab govitecan in the phase 3 ASCENT study in patients with metastatic triple-negative breast cancer (2021) (4)
- Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer (2022) (4)
- Chemotherapy (CTX) treatment patterns for early-stage breast cancer (ESBC): Changing use of anthracyclines (A). (2013) (4)
- Heritage, a phase III safety and efficacy trial of the proposed trastuzumab biosimilar, Myl-1401O vs trastuzumab (2016) (4)
- Bisphosphonates and their impact on disseminated tumor cells in early stage breast cancer. (2011) (4)
- SGNLVA-001: A phase I open-label dose escalation and expansion study of SGN-LIV1A administered weekly in breast cancer. (2020) (4)
- Abstract GS1-01: Primary outcome analysis of invasive disease-free survival for monarchE: abemaciclib combined with adjuvant endocrine therapy for high risk early breast cancer (2021) (4)
- Phase Ib study to assess the safety, tolerability, and clinical activity of gedatolisib in combination with palbociclib and either letrozole or fulvestrant in women with metastatic or locally advanced/recurrent breast cancer (B2151009; NCT02684032). (2017) (4)
- Everolimus in combination with exemestane in the treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer who are refractory to letrozole or anastrozole: Preliminary results of the BOLERO-2 trial. (2011) (4)
- A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician’s choice of therapy in patients with advanced breast cancer and a germline BRCA mutation: EMBRACA subgroups by age (2018) (4)
- Abstract PD2-07: Alpelisib + letrozole in patients withPIK3CA-mutated, hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) previously treated with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + fulvestrant: BYLieve study result (2021) (4)
- Abstract GS3-04: GS3-04 Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the Phase III CAPItello-291 trial (2023) (4)
- Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer (2022) (4)
- Settings-based efficacy comparison of trastuzumab biosimilars in breast cancer: A systematic literature review. (2018) (4)
- Troponins Do Not Predict Cardiotoxicity in a Pilot Study of Adjuvant Bevacizumab (B) Plus Dose-Dense Doxorubicin/Cyclophosphamide (AC) Followed by Nanoparticle Albumin-Bound Paclitaxel (nab-P). (2009) (4)
- Personalized Management of Chemotherapy‐Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance) (2019) (4)
- Phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of adagloxad simolenin (OBI-822) and OBI-821 treatment in patients with early-stage triple-negative breast cancer (TNBC) at high risk for recurrence. (2020) (4)
- Management of chemotherapy-induced nausea and vomiting in clinical practice. (2014) (4)
- Treatment of early-stage hormone receptor-positive breast cancer. (2019) (4)
- Letrozole or anastrozole for the prevention of early recurrences in postmenopausal women with early stage breast cancer: Using number needed to treat (NNT) to compare benefit (2008) (4)
- Utility of patient-derived lymphoblastoid cell lines as an ex vivo capecitabine sensitivity prediction model for breast cancer patients (2016) (4)
- Safety of everolimus for women over 65 years of age with advanced breast cancer (BC): 12.5-mo follow-up of BOLERO-2. (2012) (4)
- Impact of taxanes on weight gain during neoadjuvant chemotherapy (Ctx) for breast cancer (BC). (2006) (4)
- Assessing Clinical Equivalence in Oncology Biosimilar Trials With Time-to-Event Outcomes (2019) (4)
- Abstract PD1-08: Oral paclitaxel and encequidar (oPac+E) versus IV paclitaxel (IVPac) in the treatment of metastatic breast cancer (mBC) patients (study KX-ORAX-001): Progression free survival (PFS) and overall survival (OS) updates (2021) (4)
- Sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (pts) with previously treated, metastatic triple-negative breast cancer (mTNBC): Final results from the phase 3 ASCENT study. (2022) (4)
- Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib? (2021) (4)
- Correction: Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients (2021) (4)
- Abstract PD2-06: Clinical outcomes of alpelisib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer withPIK3CAalterations detected in plasma ctDNA by next-generation sequencing: Biomarker analysis from the SOLAR-1 study (2021) (3)
- EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis. (2018) (3)
- New frontiers and treatment paradigms for metastatic breast cancer. A Review of an adjunct symposium of the 2011 American Society of Clinical Oncology Annual Meeting, June 4, 2011 Chicago, Illinois. (2011) (3)
- 0136 The number needed to treat to save a life: A comparison between aromatase inhibitors (2009) (3)
- A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast cancer (TNBC). (2019) (3)
- Clinical management and resolution of stomatitis in BOLERO-2. (2013) (3)
- Clinical outcomes in patients (pts) with a history of central nervous system (CNS) metastases receiving talazoparib (TALA) or physician’s choice of chemotherapy (PCT) in the phase 3 EMBRACA trial. (2021) (3)
- Phase II trial with tamoxifen in combination with vorinostat and pembrolizumab in estrogen receptor (+) hormone therapy resistant metastatic breast cancer patients (NCT02395627). (2016) (3)
- Management of abemaciclib associated adverse events in patients with hormone receptor positive (HR+), HER2- advanced breast cancer: Analysis of the MONARCH trials. (2018) (3)
- Subgroup analysis of IMpassion130: Atezolizumab + nab-paclitaxel (nab-P) in patients (pts) with advanced triple-negative breast cancer (TNBC) in Asian countries (2019) (3)
- Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer (2021) (3)
- Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance) (2021) (3)
- Abstract 859: Gene and pathway differences between MammaPrint High1/High2 risk classes: results from the I-SPY 2 TRIAL in breast cancer (2016) (3)
- Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer. (2022) (3)
- A Neoadjuvant Chemotherapy Trial for Early Breast Cancer is Impacted by COVID-19: Addressing Vaccination and Cancer Trials Through Education, Equity, and Outcomes (2021) (3)
- Abstract P3-06-05: Evaluation of anin vitroderived signature of olaparib response (PARPi-7) as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 TRIAL: (2015) (3)
- Treatment Efficacy Score - continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials. (2022) (3)
- Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry (2021) (3)
- The clinical relevance of humoral immune responses to Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 and expression of Globo H in metastatic breast cancer (2022) (3)
- Biosimilar trastuzumab-dkst monotherapy versus trastuzumab monotherapy after combination therapy: Toxicity, efficacy, and immunogenicity from the phase 3 Heritage trial. (2018) (3)
- Objective assessment of physical activity during chemotherapy for breast cancer. (2017) (3)
- A phase II trial of letrozole in combination with bevacizumab in patients with hormone receptor-positive metastatic breast cancer: Correlation of response with circulating endothelial (CEC) and epithelial cells (CTC) (2006) (3)
- Efficacy and Safety of Everolimus in Postmenopausal Women With Advanced Breast Cancer (BOLERO-2): Effect of Visceral Metastases and Prior Endocrine Therapy (2012) (3)
- Glutaminase (GLS) expression in primary breast cancer (BC): Correlations with clinical and tumor characteristics. (2019) (3)
- Prevention of stomatitis in patients with hormone receptor-positive advanced breast cancer treated with everolimus plus exemestane: A phase II study of a steroid-based mouthwash. (2014) (3)
- Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial (2022) (3)
- Abstract GS4-02: Analysis of clinical outcomes and expression-based immune signatures by race in the I-SPY 2 trial (2022) (3)
- PIK3CA mutation status and progression-free survival in advanced hormone receptor positive (HR+)/ human endocrine receptor negative (HER2–) metastatic breast cancer (mBC): A meta-analysis of published clinical trials. (2020) (3)
- Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician's choice chemotherapy treatment (PCT): A focus on the EMBRACA triple negative (TNBC) subpopulation. (2018) (3)
- P1-08-07: Survival in US Women Following an Indication of Metastatic Breast Cancer Diagnosis and Chemotherapy Initiation: A SEER-Medicare Analysis. (2011) (3)
- Trophoblast Cell Surface Antigen 2 gene (TACSTD2) expression in primary breast cancer (2022) (3)
- Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer (2022) (3)
- Alpelisib (ALP) with fulvestrant (FUL) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Primary or secondary resistance to prior endocrine therapy (ET) in the SOLAR-1 trial. (2019) (3)
- Abstract PD8-10: Efficacy and safety of enobosarm, a selective androgen receptor modulator, to target AR in women with advanced ER+/AR+ breast cancer - final results from an international Phase 2 randomized study (2021) (3)
- Strategies and Progress of Endocrine Therapy for Patients with Metastatic Breast Cancer. (2017) (3)
- Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial. (2019) (3)
- EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment. (2018) (3)
- Risk-Based Screening for Cancer in Patients With Dermatomyositis: Toward a More Individualized Approach. (2022) (3)
- SOPHIA analysis by chemotherapy (Ctx) choice: A phase III (P3) study of margetuximab (M) + Ctx versus trastuzumab (T) + Ctx in patients (pts) with pretreated HER2+ metastatic (met) breast cancer (MBC). (2020) (3)
- Phase Ib study of eribulin (ERB) and cyclophosphamide (CTX) in metastatic breast cancer (MBC). (2013) (3)
- A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1) (2016) (3)
- TBCRC 002: A phase II, randomized, open label trial of preoperative letrozole versus letrozole (LET) in combination with bevacizumab (BEV) in post-menopausal women with newly diagnosed stage II/III breast cancer. (2013) (2)
- Abstract PS13-06: Lower rates of neuropathy with oral paclitaxel and encequidar (oPac+E) compared to IV paclitaxel (IVPac) in treatment of metastatic breast cancer (mBC): Study KX-ORAX-001 (2021) (2)
- 187 – Paraneoplastic Syndromes and Other Non-Neoplastic Effects of Cancer (2012) (2)
- 5020 Pharmacokinetics (PK), safety, and efficacy of trastuzumab (T)-DM1, a HER2 antibody-drug conjugate (ADC), in patients with HER2+ metastatic breast cancer (MBC): phase I and phase II trial results (2009) (2)
- biomarkersExploratory biomarkers in MONARCH 1, a phase II study of abemaciclib monotherapy in hormone-receptor positive (HR ) HER2- metastatic breast cancer (MBC) (2016) (2)
- Pathologic complete response (pCR) rates for HR+/HER2- breast cancer by molecular subtype in the I-SPY2 Trial. (2022) (2)
- Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial (2021) (2)
- HER2-positive breast cancer: is more treatment better? (2016) (2)
- Lapatinib: new directions in HER2 directed therapy for early stage breast cancer. (2009) (2)
- The role of percutaneous vertebral augmentation in patients with metastatic breast cancer: Literature review including report of two cases (2022) (2)
- Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. (2023) (2)
- Number needed to treat (NNT) to compare benefits of letrozole (LET) with adjuvant chemotherapy (CT) in patients (pts) with node-positive (N+) breast cancer (BC). (2009) (2)
- Confirmed tumor response by molecular subtype in patients with metastatic breast cancer: Sub-analysis from a phase 3 clinical study comparing oral paclitaxel and encequidar to IV paclitaxel. (2021) (2)
- Abstract OT2-03-03: Evaluation of talazoparib, a PARP inhibitor, in patients with somaticBRCAmutant metastatic breast cancer: Genotyping based clinical trial (2020) (2)
- Abstract OT1-08-03: Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of adagloxad simolenin (OBI-822) and OBI-821 treatment in patients with early-stage triple-negative breast cancer (TNBC) at high risk for recurrence (2020) (2)
- Abstract OT2-01-07: A phase 2 open label, multi-center, multinational study investigating the efficacy and safety of GTx-024 on advanced, androgen receptor-positive triple negative breast cancer (AR+ TNBC) (2016) (2)
- Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer (2022) (2)
- Palbociclib combined with endocrine treatment in breast cancer patients with high relapse risk after neoadjuvant chemotherapy: Subgroup analyses of premenopausal patients in PENELOPE-B. (2021) (2)
- The role of targeted therapy and biomarkers in breast cancer treatment (2012) (2)
- New developments in metastatic breast cancer: general discussion. (2013) (2)
- Assessment of sacituzumab govitecan (SG) in patients with prior neoadjuvant/adjuvant chemotherapy in the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC). (2021) (2)
- Real-world use of scalp cooling to reduce chemotherapy-related hair loss. (2017) (2)
- Abstract PS10-12: Integrated safety summary of single agent and combination margetuximab in phase 1, 2, and 3 studies of HER2-positive advanced cancers and metastatic breast cancer (MBC) (2021) (2)
- Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study (2022) (2)
- The new world of biosimilars in oncology: Translation of data to the clinic. (2018) (2)
- Prognostic and predictive significance of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial. (2014) (2)
- PO112EFFICACY OF NEPA, THE FIRST COMBINATION ANTIEMETIC AGENT, IN PATIENTS WITH BREAST CANCER RECEIVING ANTHRACYCLINE/CYCLOPHOSPHAMIDE (AC) OR NON-AC CHEMOTHERAPY (2015) (2)
- Abstract OT1-04-04: A phase 2 randomized, double-blind, placebo-controlled trial of endocrine therapy ± radium-223 dichloride in HER2-negative, hormone receptor–positive breast cancer patients with bone metastases (2017) (2)
- Patient-reported outcomes (PROs) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) from SOLAR-1. (2019) (2)
- Abstract PD2-12: Palbociclib in combination with fulvestrant or tamoxifen as treatment for hormone receptor positive (HR+) metastatic breast cancer (MBC) with prior chemotherapy for advanced disease (TBCRC 035) A phase II study with pharmacodynamics markers (2019) (2)
- 267P Phase Ib/II open-label, randomized evaluation of second- or third-line (2L/3L) atezolizumab (atezo) + entinostat (entino) in MORPHEUS-HR+ breast cancer (M-HR+BC) (2021) (2)
- Emerging data on improving response to hormone therapy: the role of novel targeted agents (2018) (2)
- Abstract PD13-02: Phase Ib expansion study of gedatolisib in combination with palbociclib and endocrine therapy in women with ER+ metastatic breast cancer (2022) (2)
- Abstract OT2-01-11: A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in human epidermal growth factor receptor 2–negative, hormone receptor–positive breast cancer patients with bone metastases (2016) (2)
- Abstract CT072: Exploration of impact of tumorBRCAzygosity and genomic loss-of-heterozygosity (gLOH) on efficacy in Phase 3 EMBRACA study of talazoparib in patients (pts) with HER2-negative (HER2−) advanced breast cancer (ABC) and a germlineBRCA1/2(gBRCA1/2) mutation (2020) (2)
- Role of pazopanib (PZ) in modulating hormone resistance in advanced breast cancer (ABC). (2015) (2)
- Hematologic adverse events following palbociclib (PAL) dose reduction in patients (pts) with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2‒) advanced breast cancer (ABC): Pooled analysis from randomized phase 2 and 3 studies. (2018) (2)
- Cyclin-dependent kinase 4/6 inhibition in the treatment of hormone receptor-positive breast cancer. (2019) (2)
- IMpassion130: Expanded safety analysis from a P3 study of atezolizumab (A) + nab-paclitaxel (nP) in patients (pts) with treatment (tx)-naïve, locally advanced or metastatic triple-negative breast cancer (mTNBC). (2019) (2)
- mage-Detected Breast Cancer : tate-ofthe-Art Diagnosis and Treatment (2009) (2)
- Cardiac Outcomes of Patients on Adjuvant Weekly Paclitaxel and Trastuzumab for Node Negative, HER2 Positive Breast Cancer (2017) (2)
- Title Identification of a Genomic Region between SLC 29 A 1 and HSP 90 AB 1 Associated with Risk of Bevacizumab-Induced Hypertension : CALGB 80405 ( Alliance ) (2018) (2)
- Abstract PS13-16: Pharmacokinetic evaluation of an oral paclitaxel DHP107 (Liporaxel®) in patients with recurrent or metastatic breast cancer (MBC): Phase II study (OPERA, NCT03326102) (2021) (2)
- Abstract P3-09-01: NEPA, a fixed-dose combination of netupitant and palonosetron, prevents chemotherapy-induced nausea and vomiting (CINV) more effectively and reduces the impact on daily living for breast cancer patients compared with palonosetron (2013) (2)
- Highlights in breast cancer from the 2017 American Society of Clinical Oncology Annual Meeting. (2017) (2)
- 1484PDMULTICYCLE EFFICACY AND SAFETY OF NEPA, A FIXED-DOSE ANTIEMETIC COMBINATION OF NETUPITANT AND PALONOSETRON, IN PATIENTS RECEIVING CHEMOTHERAPY OF VARYING EMETOGENICITY. (2014) (2)
- A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2–negative hormone receptor–positive breast cancer and bone metastases (2016) (2)
- Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: Surgical results from an international randomized trial (BrighTNess). (2017) (2)
- Prognostic role of plasma HER2 gene copy number in patients with HER2 positive metastatic breast cancer. (2018) (2)
- P331 Efficacy and safety of scalp cooling to prevent chemotherapy (CTX) induced alopecia: A review of available data (2011) (2)
- PIK3CA mutation status, progression and survival in advanced HR + /HER2- breast cancer: a meta-analysis of published clinical trials (2022) (2)
- PIM kinase inhibition presents a novel targeted therapy against triple-negative breast tumors with elevated MYC expression (2016) (2)
- Abstract OT2-01-06: Phase 2 open label, multinational, randomized, parallel design study investigating the efficacy and safety of GTx-024 on metastatic (MET) or locally advanced (LA) ER+/AR+ breast cancer (BC) in postmenopausal (PM) women (2016) (2)
- Geographic and Patient Characteristics Associated With Election of Prophylactic Mastectomy in Young Breast Cancer Patients With Early Disease (2018) (2)
- Phase I dose-escalation and expansion study of the PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumours (2019) (2)
- A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel (2019) (2)
- DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial (2017) (2)
- 248PImpact of prior treatment on palbociclib plus letrozole (P+L) efficacy and safety in patients (pts) with estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2–) first-line advanced breast cancer (ABC): A PALOMA-2 subgroup analysis (2017) (2)
- Correlation of receptor activator of nuclear factor kappa b (RANK) expression in breast cancer (BC) at the time of diagnosis with recurrence-free survival (RFS) and risk of bone-dominant metastases (BDM) in the I-SPY 1 trial (CALGB 150007/150012; ACRIN 6657). (2012) (2)
- registHER: Patient characteristics, treatment patterns, and preliminary outcomes in patients with HER2-positive (HER2+), hormone receptor-positive (HR+) metastatic breast cancer (MBC) (2007) (2)
- Prognostic associations of 25OH vitamin D in NCIC CTG MA.21, a phase III adjuvant RCT of three chemotherapy regimens (EC/T, CEF, AC/T) in high-risk breast cancer (BC). (2014) (2)
- Etirinotecan pegol (EP) target-specific pharmacodynamic (PD) biomarkers measured in circulating tumor cells (CTCs) from patients in the phase III BEACON study in patients with metastatic breast cancer (mBC). (2013) (2)
- Sacituzumab Govitecan in Metastatic Breast Cancer. Reply. (2021) (2)
- Hospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA. (2019) (2)
- Dual HER2 Blockade (2017) (2)
- Abstract P4-10-01: Quality of life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05) (2022) (1)
- Genomic and expression profiling reveal molecular heterogeneity of disseminated tumor cells in bone marrow of early breast cancer (2018) (1)
- Abstract OT-13-10: Global Phase 3 Study of Adagloxad Simolenin (OBI-822) and OBI-821 Versus Placebo Treatment for High Risk Early Stage Triple Negative Breast Cancer Patients (TNBC) Following Neoadjuvant or Adjuvant Chemotherapy (2021) (1)
- Abstract GS4-08: Clinical utility of repeated circulating tumor cell (CTC) enumeration as early treatment monitoring tool in metastatic breast cancer (MBC) - a global pooled analysis with individual patient data (2021) (1)
- Clinical characteristics and outcomes in patients with metastatic breast cancer and pseudocirrhosis: a single center retrospective cohort study (2022) (1)
- Abstract P1-18-13: Efficacy and safety of palbociclib plus endocrine therapy in Black and Hispanic patients with hormone receptor positive/human epidermal growth factor receptor 2-negative advanced breast cancer (HR+/HER2- ABC) participating in the PALOMA trials (2022) (1)
- Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Biomarker (BM) analyses by next-generation sequencing (NGS) from the SOLAR-1 study. (2022) (1)
- Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST? (2021) (1)
- 309P Real-world effectiveness of alpelisib (ALP) + fulvestrant (FUL) compared with standard treatment among patients (Pts) with hormone-receptor positive (HR+) human epidermal growth factor receptor-2 negative (HER2–) PIK3CA-mutated (Mut) advanced breast cancer (ABC) (2020) (1)
- Efficacy and Safety of Initial 5 Years of Adjuvant Endocrine Therapy in Postmenopausal Hormone Receptor-Positive Breast Cancer: A Systematic Review and Network Meta-Analysis (2022) (1)
- Abstract P1-10-06: Nausea control and quality-of-life benefit with NEPA, the first combination antiemetic agent, in patients with breast cancer receiving anthracycline/cyclophosphamide (AC) chemotherapy (2016) (1)
- Abstract CT128: Palbociclib in combination with fulvestrant or tamoxifen as treatment for hormone receptor positive metastatic breast cancer with prior chemotherapy for advanced disease (TBCRC 035): A Phase II study with pharmacodynamic markers (2019) (1)
- Clinical performance, efficacy, and safety of the DigniCap system, a scalp-hypothermia system, in preventing chemotherapy (CTX)-induced alopecia in patients (pts) with early-stage breast cancer (BC). (2011) (1)
- Emerging trends in type of chemotherapy (CT) received among patients (pts) with stage I breast cancer (BC). (2014) (1)
- Long-term survivor (LTS) characteristics in HER2+ metastatic breast cancer (MBC). (2012) (1)
- Real-world (rw) clinical outcomes on alpelisib (ALP) in patients (pts) with breast cancer (BC) and PIK3CA mutations (PIK3CAm). (2021) (1)
- Trials of Immunotherapy in Triple Negative Breast Cancer (2021) (1)
- Variations in inflammatory cytokine genes are associated with persistent severe breast pain after breast cancer surgery (2013) (1)
- Abstract PS10-35: Early intervention for and management of alpelisib (ALP)-induced hyperglycemia: Case studies from the phase III SOLAR-1 trial (2021) (1)
- The Neat-HER Virtual Registry: A novel registry following HER2+ ESBC patients receiving neratinib in the extended adjuvant setting. (2019) (1)
- Abstract OT1-04-05: A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2-negative, hormone receptor–positive breast cancer and bone metastases (2017) (1)
- Author Correction: Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer (2022) (1)
- Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study. (2019) (1)
- Exploring impact of mutations in non-BRCA DNA damage response (DDR) and non-DDR genes on efficacy in phase III EMBRACA study of talazoparib (TALA) in patients (pts) with germline BRCA1/2 mutated (gBRCAm) HER2-negative (HER2-) advanced breast cancer (ABC). (2020) (1)
- Management of breast cancer diagnosed during pregnancy: global perspectives (2022) (1)
- Abstract GS1-02: Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (2022) (1)
- Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib (2022) (1)
- Impact of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy on alpelisib (ALP) benefit in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor-2–negative (HER2–), PIK3CA-mutated advanced breast cancer (ABC) from BYLieve. (2021) (1)
- Patient-reported outcomes (PROs) from the systemic therapies for HER2-positive metastatic breast cancer (MBC) registry study (SystHERs): Eliciting the patient experience. (2014) (1)
- Abstract OT1-05-02: A phase II study to evaluate the efficacy, safety and pharmacokinetics of DHP107 (Liporaxel®, oral paclitaxel) compared to IV paclitaxel in patients with recurrent or metastatic breast cancer: OPERA (NCT03326102) (2020) (1)
- 163P Population-adjusted comparison of SOLAR-1 and BOLERO-2: PFS with second-line alpelisib + fulvestrant vs everolimus + exemestane in postmenopausal pts with PIK3CA-mut hormone-receptor positive (HR+) human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer (ABC) (2020) (1)
- Prospective study of cognitive function (cog fcn) in women with early-stage breast cancer (BC): Relationship between perceived and measurable cognitive deficits. (2013) (1)
- Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1 (2020) (1)
- Patient-reported outcomes (PROs) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): a focus on the EMBRACA HR+/HER2- subpopulation (2018) (1)
- Abstract PD13-03: Ribociclib, everolimus, exemestane triplet therapy in HR+/HER2− advanced breast cancer after progression on a CDK4/6 inhibitor: Final efficacy, safety, and biomarker results from TRINITI-1 (2022) (1)
- Abstract P5-17-06: Emotional/psychological characteristics of women with triple-negative breast cancer: Do socioeconomic, demographic, and provider variables impact emotional change from diagnosis to post-treatment? (2015) (1)
- OT3-01-16: A Phase 2 Study of Ridaforolimus (RIDA) and Dalotuzumab (DALO) in Estrogen Receptor Positive (ER+) Breast Cancer. (2011) (1)
- Trastuzumab Emtansine (T-DM1) for the Treatment of HER2-Positive Cancer with a Focus on Breast Cancer (2013) (1)
- The Risk of Early Recurrence and Distant Metastases — Lessons from the Monotherapy Adjuvant Aromatase Inhibitor Trials with a Focus on BIG 1-98 (2006) (1)
- Abstract 858: Combining sensitivity markers to identify triple-negative breast cancer patients most responsive to veliparib/carboplatin: results from the I-SPY 2 TRIAL (2016) (1)
- Abstract GS1-09: Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomes (2023) (1)
- Imaging of solid tumors using 68Ga-FAP-2286. (2022) (1)
- Contessa: A multinational, multicenter, randomized, phase 3 registration study of tesetaxel in patients (Pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (MBC). (2018) (1)
- 249PAnalysis of overall survival by tumor response in MONARCH 1, a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, in women with HR+/HER2- metastatic breast cancer (MBC) after chemotherapy for advanced disease (2017) (1)
- Health-Related Quality of Life (QOL) in Metastatic Breast Cancer Patients Treated With Everolimus and Exemestane Versus Exemestane Monotherapy (2012) (1)
- Management of Alopecia Due to Cancer Therapies (2018) (1)
- Abstract P3-11-02: Evaluation of patritumab/paclitaxel/trastuzumab over standard paclitaxel/trastuzumab in early stage, high-risk HER2 positive breast cancer: Results from the neoadjuvant I-SPY 2 trial (2020) (1)
- TBCRC 019: An open label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel (nab-PAC) with or without the anti-death receptor 5 (DR5) monoclonal antibody tigatuzumab (TIG) in patients with metastatic triple negative breast cancer (TNBC). (2013) (1)
- A phase 3, randomized, open-label study of the anti-Globo H vaccine adagloxad simolenin/obi-821 in the adjuvant treatment of high-risk, early-stage, Globo H-positive triple-negative breast cancer. (2022) (1)
- Academic and Community Cancer Research United (ACCRU) RU011301I: Adjuvant ado-trastuzumab emtansine (T-DM1) for older patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. (2016) (1)
- Evaluation of the correlation of baseline blood pressure (BP) and plasma renin activity (PRA) with bevacizumab (B)-mediated hypertension in patients with early-stage breast cancer. (2009) (1)
- PCN22 COMPARING THE SURVIVAL BENEFIT OF LETROZOLE AND ANASTROZOLE: A NUMBER NEEDED TO TREAT ANALYSIS (2009) (1)
- P4-07-17: Isolation of Highly Pure Circulating Tumor Cells (CTCs) from Metastatic Breast Cancer (MBC) Patients for Gene Expression Analysis. (2011) (1)
- Four-year follow-up of a phase III study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2-positive early or locally advanced breast cancer in neoadjuvant setting. (2020) (1)
- Abstract P1-19-16: Long-term pooled safety analysis of palbociclib in combination with endocrine therapy for hormone receptor-positive/human epidermal growth factor receptor 2–negative advanced breast cancer: An updated analysis (2020) (1)
- Abstract P2-20-02: Site of recurrence after neoadjuvant therapy: Clues to biology and impact on endpoints (2020) (1)
- Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology. (2020) (1)
- Treatment effect of palbociclib (PAL) plus endocrine therapy (ET) by prognostic and intrinsic subtype: A joint analysis of PALOMA2 and PALOMA3. (2018) (1)
- A phase 2 randomized, double-blind, placebo-controlled trial of endocrine therapy ± radium-223 dichloride (Ra-223) in HER2- hormone receptor+ breast cancer patients with bone metastases. (2015) (1)
- Abstract P4-10-09: Patient-centered dosing: Oncologists’ perspectives about treatment-related side effects and individualized dosing for patients with metastatic breast cancer (MBC) (2022) (1)
- Abstract GS1-08: The MYC oncogene suppresses tumor immune infiltration and function which is reversible with combinatorial immunotherapies (2021) (1)
- A randomized phase II study of pembrolizumab, an anti-PD (programmed cell death) 1 antibody, in combination with carboplatin compared to carboplatin alone in breast cancer patients with chest wall disease, with immunologic and genomic correlative studies. (2018) (1)
- First, do no harm: risk of secondary cancer after breast cancer treatment. (2022) (1)
- New developments in metastatic breast cancer: introduction. (2013) (1)
- O-102 Results of a phase 2 study of the oral tyrosine kinase inhibitor (TKI): axitinib (AG-013736; AG) in combination with docetaxel (DOC) vs DOC plus placebo (PL) in first-line metastatic breast cancer (MBC) (2007) (1)
- Abstract PD10-01: Patient-reported outcomes in patients with HER2- advanced breast cancer and a germlineBRCA1/2mutation receiving talazoparib vs physician’s choice of chemotherapy: A focus on EMBRACA ECOG performance status subgroups (2020) (1)
- Androgen receptor (AR) expression in primary breast cancer (BC): Correlations with clinical characteristics and outcomes. (2016) (1)
- Assessment of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) cohort by agent in the phase 3 ASCENT study of patients (pts) with metastatic triple-negative breast cancer (mTNBC). (2021) (1)
- 18PFirst stage of an on-going phase 2, open label, international, randomized, parallel design study investigating efficacy + safety of GTx-024 for advanced ER+/AR+ breast cancer (BC) (2017) (1)
- PCN21 NUMBER NEEDED TO TREAT (NNT) ANALYSIS COMPARING BENEFITS OF LETROZOLE WITH ADJUVANT CHEMOTHERAPY IN PATIENTS WITH NODE-POSITIVE BREAST CANCER (2009) (1)
- Abstract P4-15-05: Novel targeted therapy for breast cancer chest wall recurrence: Low temperature liposomal doxorubicin and mild local hyperthermia (2013) (1)
- Variations in potassium channel genes are associated with severe persistent breast pain after breast cancer surgery (2013) (1)
- A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2–negative hormone receptor–positive breast cancer and bone metastases. (2016) (1)
- Evidence-driven, patient-specific approaches for optimizing survival prolongation in breast cancer. (2014) (1)
- Patient Reported Outcomes (PRO) in patients (pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: A focus on subgroups with/ without visceral disease (2019) (1)
- Abstract OT-03-03: SGNLVA-001: A phase 1 open-label dose escalation and expansion study of SGN-LIV1A administered weekly in breast cancer (2021) (1)
- Abstract P3-10-03: Etirinotecan pegol target-specific pharmacodynamic biomarkers in circulating tumor cells from patients with metastatic breast cancer in the phase 3 BEACON study (2015) (1)
- A phase Ib/II study of eribulin with cyclophosphamide (EC) in patients (pts) with advanced breast cancer (ABC). (2020) (1)
- Abstract OT2-24-02: ZEST: Randomized phase III study evaluating efficacy and safety of niraparib in patients with HER2-negative BRCA-mutated or triple-negative breast cancer with detectable circulating tumor DNA after definitive therapy (2022) (1)
- Abstract OT1-08-09: CONTESSA: A multinational, multicenter, randomized, phase 3 registration study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane (2020) (1)
- PCN491 PATIENT REPORTED OUTCOMES (PRO) OF TALAZOPARIB (TALA) VERSUS PHYSICIAN'S CHOICE OF CHEMOTHERAPY (PCT) IN PATIENTS (PTS) WITH ADVANCED BREAST CANCER (ABC) AND A GERMLINE BRCA (GBRCA) MUTATION: A FOCUS ON EMBRACA PTS WITH/ WITHOUT PRIOR CHEMOTHERAPY (CT) SUBGROUPS (2019) (1)
- Decreased enrollment of patients with advanced lobular breast cancer compared to ductal breast cancer in interventional clinical trials. (2021) (1)
- PATIENT-REPORTED OUTCOMES (PRO) IN PATIENTS (PTS) WITH HER2− ADVANCED BREAST CANCER (ABC) RECEIVING TALAZOPARIB (TALA) VS PHYSICIAN’S CHOICE CHEMOTHERAPY (PCT): A FOCUS ON EMBRACA GERMLINE BRCA1 AND BRCA2 MUTATION (GBRCA1/2M) SUBGROUPS (2019) (1)
- Programmed cell death 1 (PD-1) receptor and programmed death ligand 1 (PD-L1) expression in primary breast cancer (BC); correlations with clinical characteristics and patient outcomes. (2015) (1)
- Phase II multicenter study of talazoparib for somatic BRCA1/2 mutant metastatic breast cancer. (2021) (1)
- 109P Updated Results of the Bolero-2 Phase Iii Trial Evaluating Everolimus (Eve) for Postmenopausal Women with Advanced Breast Cancer (Abc) (2012) (1)
- Next-generation DNA sequencing (NGS) results for tumours from phase II ABRAZO study of talazoparib after platinum or cytotoxic non-platinum regimens in patients (pts) with advanced breast cancer (ABC) and germline BRCA1/2 (gBRCA) mutations (2019) (1)
- The 21-Gene Recurrence Score in Clinically High-Risk Lobular and Ductal Breast Cancer: A National Cancer Database Study (2022) (1)
- Mitotic score and pleomorphic histology in invasive lobular carcinoma of the breast: impact on disease-free survival (2020) (1)
- Pembrolizumab plus chemotherapy in triple-negative breast cancer – Authors' reply (2021) (1)
- Phase III open-label, randomized, multicenter study of NKTR-102 versus treatment of physician's choice (TPC) in patients (pts) with locally recurrent or metastatic breast cancer (MBC) previously treated with an anthracycline, a taxane, and capecitabine (ATC). (2012) (1)
- Phase II trial of a PARP inhibitor in somatic BRCA mutant metastatic breast cancer. (2020) (1)
- 1571P COVID-19 positivity rates in patients with an active cancer diagnosis in the University of California Cancer Consortium (2021) (1)
- Neoadjuvant therapy for HER2-positive early-stage breast cancer: the future is almost here. (2012) (1)
- NCCN Antiemesis Panel Members (2010) (1)
- Abstract 1591: Comprehensive molecular profiling of circulating tumor cells from metastatic breast cancer patients (2015) (1)
- Biomarkers for Cyclin-Dependent Kinase 4/6 Inhibitors in the Treatment of Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced/Metastatic Breast Cancer: Translation to Clinical Practice (2022) (1)
- Results from CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel (T) plus a reduced dose of capecitabine (C) in patients (pts) with hormone receptor + (HR+), HER2- metastatic breast cancer (MBC) not previously treated with a taxane. (2021) (1)
- CONTESSA: A multinational, multicenter, randomized, phase III registration study of tesetaxel plus a reduced dose of capecitabine in patients (pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (LA/MBC) who have previously received a taxane. (2019) (1)
- Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study (2012) (1)
- Molecular subtype to predict pathologic complete response in HER2-positive breast cancer in the I-SPY2 trial. (2022) (1)
- A randomized trial evaluating the integration of online questionnaires into follow-up (FU) care for early-stage breast cancer (ESBC). (2012) (1)
- Use of Neoadjuvant Platinum-The Ongoing Conundrum. (2017) (1)
- The Role of Immunotherapy in the Treatment of Triple Negative Breast Cancer (TNBC) (2017) (1)
- Exhausted CD8+ cells (Tex) to predict response to PD-1 therapy in estrogen receptor (+) hormone therapy resistant breast cancer predictive of response to immune checkpoint inhibitors after epigenetic priming. (2018) (1)
- Abstract PD9-05: Lack of background parenchymal enhancement suppression in breast MRI during neoadjuvant chemotherapy may be associated with inferior treatment response in hormone receptor positive breast cancer (2020) (0)
- Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2− advanced breast cancer: a matching-adjusted indirect comparison (2023) (0)
- The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer (2014) (0)
- High-dose chemotherapy for peripheral stem cell procurement in leukemia, lymphoma and multiple myeloma. (1994) (0)
- TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer (2020) (0)
- Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer (2022) (0)
- Abstract OT-30-01: KEYLYNK-009: A phase 2/3, open-label, randomized study of pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with first-line pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) (2021) (0)
- Abstract P4-01-13: Practice patterns of MRI utilization for breast cancer treatment within the University of California system as part of the Athena initiative (2012) (0)
- Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer (2022) (0)
- Methylomes variation to predict exemestane resistance in advanced breast cancer. (2018) (0)
- Abstract PD8-07: Evaluation of Tucatinib + (Paclitaxel + Pertuzumab + Trastuzumab) followed by AC in high-risk HER2 positive (HER2+) stage II/III breast cancer: Results from the I-SPY 2 TRIAL (2022) (0)
- Dr. Hope S. Rugo on the SOPHIA Trial in HER2+ Breast Cancer (2019) (0)
- Characterizing attitudes related to child-bearing in young women diagnosed with early breast cancer (EBC). (2021) (0)
- Abstract OT2-3-04: A PILOT PHASE II STUDY TO EVALUATE THE IMPACT OF DENOSUMAB ON DISSEMINATED TUMOR CELLS (DTC) IN PATIENTS WITH EARLY STAGE BREAST CANCER (ESBC) (2012) (0)
- NCCN Senior Adult Oncology , Version 2 . 2014 Clinical Practice Guidelines in Oncology (2014) (0)
- Abstract GS1-11: Sacituzumab Govitecan (SG) vs Treatment of Physician’s Choice (TPC): Efficacy by Trop-2 Expression in the TROPiCS-02 Study of Patients (Pts) With HR+/HER2– Metastatic Breast Cancer (mBC) (2023) (0)
- Highlights in breast cancer from the 2016 American Society of Clinical Oncology Annual Meeting. (2016) (0)
- Senior Adult OncologyPractice Guidelines in Oncology (2012) (0)
- Evaluation of the Pathways for Survivors Program to Address Breast Cancer Survivorship–Associated Distress: Survey Study (2021) (0)
- Treating Advanced Breast Cancer in the Older Woman: Review 2 (2006) (0)
- Abstract P1-18-11: Analysis of first-line (1L) patients (pts) with de novo disease vs late relapse and all pts with vs without prior chemotherapy (CT) in the MONALEESA-3 (ML-3) trial (2022) (0)
- Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial (2021) (0)
- Primary outcome analysis of invasive disease-free survival for monarchE: abemaciclib plus adjuvant endocrine therapy for high-risk early breast cancer (2021) (0)
- Abstract PD2-04: Molecular plasticity of luminal breast cancer and response to CDK 4/6 inhibition - The biomarker program of the PENELOPE-B trial investigating post-neoadjuvant palbociclib (2022) (0)
- 5026 POSTER DISCUSSION Sorafenib (SOR) Plus Chemotherapy (CRx) for Treatment (tx) of Patients (pts) With HER2-negative Locally Advanced (adv) or Metastatic (met) Breast Cancer (BC) and Prior Bevacizumab (BEV): Subgroup Analysis of AC01B07 (2011) (0)
- Change in Topoisomerase 1–Positive Circulating Tumor Cells Affects Overall Survival in Patients withAdvancedBreastCancerafterTreatmentwith (2018) (0)
- Abstract PD9-04: Identification of biomarkers associated with therapeutic resistance: Quantitative protein/phosphoprotein analysis of ~750 patients across 8 arms of the neoadjuvant I-SPY 2 TRIAL for high-risk early stage breast cancer (2021) (0)
- CLO21-017: Hospitalization and Supportive Care Measure (SCM) Utilization in Patients With Germline BRCA1/2 Mutated (gBRCA1/2mut) HER2- Advanced Breast Cancer (ABC) in EMBRACA: Results From an Extended Follow-up Post-hoc Analysis (2021) (0)
- 68TiP KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) + olaparib (ola) vs pembro + chemotherapy after induction with first-line (1L) pembro + chemo in patients (pts) with locally recurrent inoperable or metastatic TNBC (2020) (0)
- Long term follow up (LTFU) of adjuvant zoledronic acid (ZOL) in high risk early stage breast cancer (ESBC) defined by bone marrow (BM) disseminated tumor cells (DTC). (2017) (0)
- Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast Carcinoma (2022) (0)
- Preliminary evidence of an association between candidate channel genes and preoperative breast pain in women with breast cancer (2012) (0)
- Hormonal therapy for advanced breast cancer. (2007) (0)
- Advance care planning in community: Evaluation of a two-session workshop. (2017) (0)
- 258P Analysis of patients (pts) without an initial triple-negative breast cancer (TNBC) diagnosis (Dx) in the phase III ASCENT study of sacituzumab govitecan (SG) in brain metastases-negative (BMNeg) metastatic TNBC (mTNBC) (2021) (0)
- Reconceptualizing Risk-Benefit Assessment of Novel Cancer Therapies to Expand Global Access and Reduce Worldwide Mortality. (2021) (0)
- Dexamethasone to prevent everolimus-induced stomatitis (Alliance MIST Trial: A221701). (2023) (0)
- Abstract PS13-11: Oral paclitaxel and encequidar (oPac+E) in the treatment of metastatic breast cancer (mBC): Management of gastrointestinal adverse events (GI AE). Study KX-ORAX-001 (2021) (0)
- Abstract PS4-08: Biomarker analysis of paclitaxel, ganitumab, and metformin (PGM) therapy in the I-SPY2 neoadjuvant clinical trial (2021) (0)
- Longitudinal Trajectories of Memory Performance in Patients with Early-Stage Breast Cancer (2022) (0)
- 96MO A risk analysis of alpelisib (ALP)-induced hyperglycemia (HG) using baseline factors in patients (pts) with advanced solid tumours and breast cancer (BC): A pooled analysis of X2101 and SOLAR-1 (2021) (0)
- Differences in psychosocial factors among diverse women enrolled in a phase III cooperative group metastatic breast cancer trial (CALGB 40502/Alliance). (2013) (0)
- Abstract PD9-04: Breast cancer subtype specific association of pCR with MRI assessed tumor volume progression during NAC in the I-SPY 2 trial (2020) (0)
- Abstract OT2-01-03: ELEVATE: A phase 1b/2, open-label, umbrella study evaluating elacestrant in various combinations in women and men with metastatic breast cancer (mBC) (2023) (0)
- Implementing the Promise of Personalized Cancer Care: Highlights From the Inaugural Conference of the Global Biomarkers Consortium (2012) (0)
- Abstract P1-18-04: Phase 3 SOPHIA study of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies: Infusion time substudy results (2020) (0)
- Immunotherapy and chemotherapy combination for chest wall disease: TBCRC 044 trial. (2020) (0)
- Abstract P6-02-01: The effect of background parenchymal enhancement on the predictive performance of functional tumor volume measured in MRI (2020) (0)
- 137TiP A phase III study of alpelisib and fulvestrant for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1) (2016) (0)
- Abstract PD13-01: Balixafortide (a CXCR4 antagonist)+eribulin versus eribulin alone in patients with HER2 negative, locally recurrent or metastatic breast cancer: An international, randomized, phase 3 trial (FORTRESS) (2022) (0)
- P01.02 Trastuzumab Deruxtecan Plus Pembrolizumab in Advanced/Metastatic Breast or Non-Small Cell Lung Cancer: A Phase 1b Study (2021) (0)
- A comparative effectiveness analysis of single-agent cytotoxics in triple-negative metastatic breast cancer patients. (2014) (0)
- Corrigendum to “Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studies” [Breast 41S1 (2018) S11–12] (2020) (0)
- CLO20-052: Hospitalization and Supportive Care Medication (SCM) Utilization Among Patients Treated With Talazoparib (TALA) Monotherapy: An Integrated Analysis of Five Clinical Trials (Phase 1-3) in Advanced Cancers (2020) (0)
- Abstract PD17-06: Immunohistochemical markers and determinants of clinical response in the Penelope-B trial (2023) (0)
- Abstract PD13-05: PD13-05 Updated results of a Phase 1b study of gedatolisib plus palbociclib and endocrine therapy in women with hormone receptor positive advanced breast cancer: Subgroup analysis by PIK3CA mutation status (2023) (0)
- Next steps: Incorporating patient-reported outcomes into palliative care referral for people with advanced breast cancer. (2018) (0)
- Abstract OT1-08-08: CONTESSA TRIO: A multinational, multicenter, phase 2 study of tesetaxel plus 3 different PD-(L)1 inhibitors in patients with metastatic triple-negative breast cancer (TNBC) and tesetaxel monotherapy in elderly patients with HER2- metastatic breast cancer (MBC) (2020) (0)
- Abstract P2-12-12: Efficacy and safety of scalp cooling (SC) treatment for alopecia prevention in women receiving chemotherapy (CTX) for breast cancer (BC). (2012) (0)
- BOLERO-2: Everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone receptor-positive breast cancer. (2012) (0)
- Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis. (2023) (0)
- Still Refining Adjuvant Endocrine Therapy in Premenopausal Women: Not Too Much, Not Too Little. (2016) (0)
- Reply to the letter to the editor 'Reporting of HRQoL results from the PALOMA-2 trial: unfounded conclusions due to highly biased analyses' by Kaiser et al. (2018) (0)
- Strategies for promoting advocacy engagement in the Bay Area Physical Sciences Oncology Center (PS-OC) setting. (2012) (0)
- Preliminary analysis of an expanded access study of the fixed-dose combination of pertuzumab (P) and trastuzumab (H) for subcutaneous injection (PH FDC SC) for at-home administration (admin) in patients (pts) with HER2-positive (HER2+) breast cancer (BC) during the COVID-19 pandemic. (2022) (0)
- Abstract P1-11-01: Trastuzumab deruxtecan vs treatment of physician’s choice in patients with HER2-low unresectable and/or metastatic breast cancer: Subgroup analyses from DESTINY-Breast04 (2023) (0)
- Abstract OT1-11-01: Phase II study of talazoparib, a PARP inhibitor, in somatic BRCA1/2 mutant metastatic breast cancer identified by cell-free DNA or tumor tissue genotyping (2023) (0)
- Abstract OT-33-01: Combination ipatasertib and atezolizumab to prevent recurrence in triple negative breast cancer(TNBC): A phase II single arm trial (2021) (0)
- Abstract OT3-26-02: A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a non-steroidal aromatase inhibitor (VIKTORIA-1) (2023) (0)
- Netupitant/palonosetron (NEPA) for prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in multiple cycles of chemotherapy. (2015) (0)
- Abstract PS18-23: Population pharmacokinetics (Pop PK) of MYL-1401O (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2-positive metastatic breast cancer (mBC) (2021) (0)
- Hope Rugo, MD, On the Future of Breast Cancer Treatment (2020) (0)
- Role of Immunotherapy in Breast Cancer. (2023) (0)
- Abstract PS9-28: Patient knowledge, attitudes and perceptions regarding breast cancer biomarkers, testing, and quality of life (2021) (0)
- Abstract GS1-07: Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial (2022) (0)
- Abstract P6-13-01: Lyso-thermosensitive liposomal doxorubicin + local hyperthermia for radiation-pretreated chest wall recurrence (2012) (0)
- Clinical outcomes in patients (pts) with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) with objective response (OR) or without objective response (non-OR) in PALOMA-2. (2018) (0)
- Improving Surgical / Medical Oncology Collaboration for Breast Cancer Treatment Planning : Pilot Testing the Impact of Continuing Education and Patient Care Planning (2015) (0)
- Abstract P5-16-07: Assessment of sacituzumab govitecan (SG) in Black patients (pts) from the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC) (2022) (0)
- Abstract P6-10-06: Amsterdam 70-gene profile (MammaPrint) low risk, even in the HER2 positive subset, identifies a population of women with lower early risk for recurrence despite low response rates to chemotherapy and to HER2 targeted therapy (2020) (0)
- Abstract PS9-11: Health-related quality of life for margetuximab + chemotherapy vs. trastuzumab + chemotherapy in the phase 3 SOPHIA trial of patients with pretreated HER2+ metastatic breast cancer (2021) (0)
- Abstract P1-19-29: An integrated safety analysis of talazoparib monotherapy from five clinical trials (phase 1-3) in advanced cancers (2020) (0)
- Lifestyle Changes and Breast Cancer Risks (2010) (0)
- DNA repair the 70-gene ultra-high risk as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial. (2017) (0)
- Highlights from the 2019 San Antonio Breast Cancer Symposium. (2020) (0)
- HEMATOLOGY/ONCOLOGY CLINICS (2007) (0)
- Abstract P3-01-15: Real-world effectiveness of palbociclib plus aromatase inhibitors (AI) in African American (AA) patients with metastatic breast cancer (MBC) (2023) (0)
- 338TiP CAPItello-292: A phase 1b/3 study of capivasertib, palbociclib and fulvestrant versus placebo, palbociclib and fulvestrant in HR+/HER2− advanced breast cancer (2021) (0)
- TRIPLE NEGATIVE BREAST CANCER: CURRENT STANDARDS AND OPTIMAL MANAGEMENT (2019) (0)
- Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer (2021) (0)
- Abstract P1-18-23: Evaluating the potential utility of presenting breast cancer clinical investigator estimates for numeric treatment benefit and recommendations for the use of two anti-HER2 adjuvant therapies: HER RISK (2020) (0)
- Title Synchronous Breast Implant-associated Anaplastic Large Cell Lymphoma and Invasive Carcinoma : Genomic Profiling and Management Implications (2019) (0)
- Abstract P4-07-65: Effect of sacituzumab govitecan vs chemotherapy in HR+/HER2- metastatic breast cancer: patient-reported outcomes from the TROPiCS-02 trial (2023) (0)
- Novel Therapeutic Interventions Early in the Disease Trajectory: Drug Development Beyond the Refractory Setting (2020) (0)
- Abstract OT-13-09: Translational breast cancer research consortium 044 trial: Randomized phase 2 study of pembrolizumab and carboplatin versus carboplatin alone for chest wall recurrence of breast cancer (2021) (0)
- Abstract P3-01-14: Real-world treatment patterns of Palbociclib plus an aromatase inhibitor or aromatase inhibitor alone for metastatic breast cancer in the Flatiron database (2023) (0)
- 275PFirst-line treatment patterns by age for patients (pts) with HER2+ metastatic breast cancer (MBC) in the SystHERs registry (2017) (0)
- Reply to G.-F. Li et al, K. Altundag, and N. SG et al. (2023) (0)
- Abstract PS14-01: Radium-223 in women with HR-positive bone-metastatic breast cancer receiving endocrine therapy: International phase 2, randomized, double-blind, placebo-controlled trial (2021) (0)
- Mechanisms of action and acquired resistance to atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer (mTNBC). (2022) (0)
- Abstract P3-06-25: MammaPrint High1/High2 risk class as a biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy for breast cancer in the I-SPY 2 TRIAL (2015) (0)
- ATTAIN: Phase 3 study of etirinotecan pegol (EP) vs. treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC). (2017) (0)
- Does the cancer geriatric assessment (GA) introduce bias into clinical trials? Observations from 988 prospectively recruited patients. (2021) (0)
- Clinical and radiographic characteristics of patients with metastatic breast cancer and pseudocirrhosis: A single-center retrospective cohort study. (2022) (0)
- Abstract P5-16-06: A first-in-human phase 1/2a dose escalation/expansion study of the first-in-class CDK2/4/6 inhibitor PF-06873600 alone or with endocrine therapy in patients with breast or ovarian cancer (2022) (0)
- Abstract P5-09-10: Preferences in educational topics of interest for women with breast cancer: Does income level influence topic preferences? (2016) (0)
- Clinical significance of circulating tumor cells (CTCs) in hormone receptor-positive (HR+) metastatic breast cancer (MBC) patients (pts) receiving letrozole (Let) or Let plus bevacizumab (Bev): CALGB 40503 (Alliance). (2019) (0)
- Abstract PS10-24: Infusion related reactions in the phase 3 SOPHIA trial of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with pretreated HER2+ metastatic breast cancer (2021) (0)
- Experience and impact of alopecia in patients (pts) with HER2+ metastatic breast cancer (MBC) in the SystHERs registry. (2017) (0)
- 136TiP IMpassion130: Phase III trial comparing 1L atezolizumab with nab-paclitaxel versus placebo with nab-paclitaxel in treatment-naive patients with mTNBC (2016) (0)
- Abstract P1-11-18: Measuring severe anxiety in patients with metastatic breast cancer: Living up to the PROMIS (2019) (0)
- Abstract IA24: Setting the stage for immunotherapy in breast cancer: where are we and where are we going in the clinic? (2018) (0)
- Meeting the educational needs of women with triple-negative breast cancer (TNBC). (2015) (0)
- 359TiP International phase III trial: Balixafortide (a CXCR4 antagonist) + eribulin versus eribulin alone in patients with HER2-negative, locally recurrent or metastatic breast cancer (FORTRESS) (2020) (0)
- Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis (2022) (0)
- Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy. (2023) (0)
- Chemotherapy treatment patterns for early-stage breast cancer (ESBC): Decreasing use of anthracycline-based regimens. (2012) (0)
- ASO Visual Abstract: The 21-Gene Recurrence Score in Clinically High Risk Lobular and Ductal Breast Cancer—A National Cancer Database Study (2022) (0)
- Abstract P5-16-15: Post-progression therapy outcomes in patients (pts) from the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC) (2022) (0)
- Multi-center randomized study of pembrolizumab/carboplatin versus carboplatin alone in patients with chest wall disease from breast cancer: TBCRC 044. (2021) (0)
- INTEGRATED SYSTEMS AND TECHNOLOGIES 30 Genomic Profiling of Isolated Circulating Tumor Cells from Metastatic Breast Cancer Patients (2012) (0)
- High-dose chemotherapy and autologous hematopoietic stem cell transplant for women with breast cancer and 10 or more involved axillary lymph nodes: Long-term follow-up (2008) (0)
- Efficacy and safety of initial five years of adjuvant endocrine therapy in postmenopausal hormone receptor-positive breast cancer: A systematic review and network meta-analysis. (2022) (0)
- Evaluation of the Pathways for Survivors program to address breast cancer survivorship associated distress (Preprint) (2021) (0)
- Emotional/psychological characteristics of women diagnosed with breast cancer following treatment: Participation versus nonparticipation in survivorship programs. (2016) (0)
- IN08 TREATMENT ASSOCIATED RISKS: IDENTIFYING AND TREATING PULMONARY TOXICITY (2015) (0)
- The Neat-HER virtual registry: Updated results on HER2+ breast cancer patients receiving neratinib as extended adjuvant therapy. (2021) (0)
- Abstract P2-11-04: Education and information preferences for women with triple-negative breast cancer: Should personal or medical demographic variables impact program tailoring? (2015) (0)
- Breast Cancer Recurrences at the Chest Wall (BCRCW) When Standard Treatments (TX) Have Failed: Lyso-Thermosensitive Liposomal Doxorubicin (LTLD) + Mild Local Hyperthermia (MLH) (2012) (0)
- Interpreting Advanced Breast Cancer Consensus Guidelines for Use in China (2016) (0)
- Tumor cell-adipocyte gap junctions activate lipolysis in breast cancer (2018) (0)
- PO134 ANALYSIS OF PRIMARY BREAST CANCER (BC) EXPRESSION OF PROGRAMMED CELL DEATH 1 (PD-1) RECEPTOR AND PROGRAMMED DEATH LIGAND 1 (PD-L1) TO DETERMINE ASSOCIATIONS WITH CLINICAL CHARACTERISTICS AND OUTCOMES (2015) (0)
- Abstract OT1-03-04: Datopotamab deruxtecan (Dato-DXd), a TROP2 antibody-drug conjugate, vs investigators’ choice of chemotherapy in previously-treated, inoperable or metastatic HR+/HER2– breast cancer: TROPION-Breast01 (2023) (0)
- Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer (2023) (0)
- A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer (2022) (0)
- CONTESSA TRIO: A multinational, multicenter, phase (P) II study of tesetaxel (T) plus three different PD-(L)1 inhibitors in patients (Pts) with metastatic triple-negative breast cancer (TNBC) and tesetaxel monotherapy in elderly pts with HER2-metastatic breast cancer (MBC). (2020) (0)
- COVID-19 Outcomes Among Patients With Cancer: Observations From the University of California Cancer Consortium COVID-19 Project Outcomes Registry (2022) (0)
- Abstract PD11-01: PD11-01 Evaluation of the PD-1 Inhibitor Cemiplimab in early-stage, high-risk HER2-negative breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL (2023) (0)
- ODAC backs yanking avastin indication in MBC: Commentary (2011) (0)
- MRI PHENOTYPES PREDICT RESPONSE AND RECURRENCE IN LOCALLY ADVANCED BREAST CANCER TREATED WITH NEOADJUVANT CHEMOTHERAPY. (2003) (0)
- Assessing Unique Risk Factors for COVID-19 Complications Among Cancer Patients: A Multi-ethnic Cohort Study (2022) (0)
- Abstract PD18-09: ACE-Breast-03: Efficacy and safety of ARX788 in patients with HER2+ metastatic breast cancer previously treated with T-DM1 (2023) (0)
- An overview of adverse event (AE) management for patients (pts) receiving abemaciclib. (2022) (0)
- Prolonging the life of people with metastatic breast cancer in routine clinical practice by adding palbociclib to an aromatase inhibitor from a real-world database analysis: a plain language summary. (2023) (0)
- Correction: Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients (2021) (0)
- Abstract P5-13-08: Identification of PD-L1+ status as a candidate predictive biomarker of response to talazoparib (TALA) in the phase 3 EMBRACA study (2022) (0)
- P182 NEPA, a new combination antiemetic, exhibits sustained efficacy over repeated chemotherapy cycles (2015) (0)
- Abstract OT2-01-05: A phase 2 randomized, double-blind, placebo-controlled trial of hormone therapy ± radium-223 dichloride in human epidermal growth factor receptor 2–negative, hormone receptor–positive breast cancer patients with bone metastases (2016) (0)
- Abstract PD14-05: Genomic profiling and clinical outcomes with first-line atezolizumab andnab-paclitaxel in triple-negative breast cancer: An exploratory analysis from the phase 3 IMpassion130 trial (2021) (0)
- P4-13-03: Retrospective Analysis of Palonosetron Compared with Older 5-HT3 Receptor Antagonists (Ondansetron, Dolasetron, and Granisetron) in Preventing Anthracycline-Induced Nausea and Vomiting in Breast Cancer Patients from Four Phase 3 Trials. (2011) (0)
- Abstract P5-02-32: Differential Gene Mutation Landscape in Patients With PIK3CA-altered and Non-altered Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer in the SOLAR-1 Clinical Study (2023) (0)
- Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer (2022) (0)
- Characterization of long-term responders following treatment with talazoparib (TALA) or physician’s choice of chemotherapy (PCT) in the phase 3 embraca trial. (2021) (0)
- Informational Needs of Patients with Metastatic Breast Cancer: What Questions Do They Ask, and Are Physicians Answering Them? (2013) (0)
- Abstract OT2-01-07: evERA Breast Cancer: A phase III study of giredestrant (GDC-9545) + everolimus vs exemestane + everolimus in patients with estrogen receptor+, HER2– locally advanced or metastatic breast cancer (2023) (0)
- Abstract PD10-04: Phase Ib/II open-label, randomized trial of atezolizumab (atezo) with ipatasertib (ipat) and fulvestrant (fulv) vs control in MORPHEUS-HR+ breast cancer (M-HR+ BC) and atezo with ipat vs control in MORPHEUS triple negative breast cancer (M-TNBC) (2022) (0)
- Abstract B34: PIM kinase as a novel therapeutic target for triple-negative breast cancer (2016) (0)
- Abstract A03: Relieving immune suppressive pathways in breast cancer to improve outcomes (2020) (0)
- New Developments in Therapy for Advanced and Metastatic Breast Cancer (2006) (0)
- Abstract P5-05-05: Monitoring for response and recurrence in neoadjuvant-treated hormone receptor-positive HER2-negative breast cancer by personalized circulating tumor DNA testing (2023) (0)
- Alpelisib (ALP) + fulvestrant (FUL) in hormone-receptor positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Subgroup analysis by presence of visceral metastasis (VM) in the SOLAR-1 trial (2019) (0)
- Abstract PS5-07: A retrospective analysis of association ofMYCandRAD21amplification with final overall survival (OS) data in the phase 3 EMBRACA study with talazoparib (2021) (0)
- Dissecting the contributions of tumor heterogeneity on metastasis at single-cell resolution (2022) (0)
- Abstract PD18-01: Adjuvant Trastuzumab Emtansine Versus Paclitaxel plus Trastuzumab for Stage I HER2+ Breast Cancer: 5-year results and correlative analyses from ATEMPT (TBCRC033) (2023) (0)
- Magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer (2019) (0)
- Trial in progress: A phase 3, randomized, double-blind trial of trilaciclib versus placebo in patients receiving first- or second-line gemcitabine and carboplatin for locally advanced unresectable or metastatic triple-negative breast cancer (PRESERVE 2). (2021) (0)
- THE ALPELISIB (ALP) EXPERIENCE IN THE SOLAR-1 AND BYLIEVE STUDIES: PERSPECTIVES FOR PRACTITIONERS CARING FOR PATIENTS (PTS) WITH HORMONE RECEPTOR-POSITIVE (HR+), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2–) ADVANCED BREAST CANCER (ABC) (2021) (0)
- Etirinotecan pegol (EP) significantly improves overall survival in patients with advanced breast cancer (aBC) and a history of brain metastases (BM) (2016) (0)
- SA 9.1 Optimal neoadjuvant and adjuvant therapy for patients with early triple negative breast cancer (2023) (0)
- Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer (2022) (0)
- Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice (2021) (0)
- DNA repair deficiency biomarkers and identification of ER-positive breast cancer patients who may benefit from veliparib/carboplatin: Results from the I-SPY 2 trial. (2017) (0)
- Abstract P2-15-02: Web-Based Patient-Intake Process for Breast Care Center: The Patient Experience (2010) (0)
- Referral patterns among patients with metastatic breast cancer in an integrated palliative care program. (2016) (0)
- Abstract HER2-06: HER2-06 Outcome analysis of HER2-zero or HER2-low hormone receptor-positive (HR+) breast cancer patients - characterization of the molecular phenotype in combination with molecular subtyping (2023) (0)
- Highlights in breast cancer from the 2018 American Society of Clinical Oncology annual meeting. (2018) (0)
- Real-world comparative effectiveness of palbociclib plus letrozole versus letrozole in older patients with metastatic breast cancer (2023) (0)
- 2049 POSTER Adjuvant therapy for early stage breast cancer (EBC): distant disease-free survival (DDFS) as a predictor of overall survival (OS) (2007) (0)
- Long-term (LT) disease control in patients (pts) with hormone receptor-positive (HR+), PIK3CA-altered advanced breast cancer (ABC) treated with alpelisib (ALP) + fulvestrant (FUL). (2021) (0)
- Variations in potassium channel genes are associated with persistent mild breast pain after breast cancer surgery (2013) (0)
- Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial (2022) (0)
- Abstract P2-01-05: Parallel DNA and RNA profiling of EpCAM-positive cells in blood of metastatic breast cancer (MBC) patients confirm their malignant nature (2012) (0)
- Abstract P5-15-01: Evaluation of sustained antiemetic efficacy over repeated cycles of anthracycline-cyclophosphamide (AC)-based chemotherapy: A phase 3 study of NEPA, a fixed-dose combination of netupitant and palonosetron for prevention of chemotherapy-induced nausea and (2015) (0)
- APhase II Trial of Erlotinib in Combinationwith Bevacizumab in Patients withMetastatic Breast Cancer (2008) (0)
- Abstract OT2-24-03: Phase II study of a PARP inhibitor in metastatic breast cancer with somaticBRCA1/2mutations identified by cell-free DNA: Genotyping based clinical trial (2022) (0)
- Abstract OT3-31-01: The Amelia-1 Study: A phase 1b/2 trial of evexomostat (SDX-7320) plus fulvestrant (Faslodex®) and alpelisib (Piqray®) in patients with advanced breast cancer at risk for alpelisib (Piqray)-induced hyperglycemia (2023) (0)
- Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3. In Reply to Badoui, et al. (2021) (0)
- Abstract OT1-08-07: CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, HR+ metastatic breast cancer (MBC) who have not previously received a taxane (2020) (0)
- Racial disparities in treatment patterns and clinical outcomes in patients (pts) with HER2+ metastatic breast cancer (MBC). (2012) (0)
- Highlights in the management of breast cancer from the 2012 San Antonio Breast Cancer Symposium (SABCS). (2013) (0)
- Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies (2020) (0)
- GLORIA: phase III, open-label study of adagloxad simolenin/OBI-821 in patients with high-risk triple-negative breast cancer. (2022) (0)
- Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance) (2017) (0)
- P5-14-04: RANK Expression in Primary Tumor Tissue at the Time of Diagnosis Correlates with Risk of Subsequent Bone Metastases in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657). (2011) (0)
- Abstract OT1-18-06: KEYNOTE-B49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2− locally recurrent inoperable or metastatic breast cancer (2022) (0)
- Title: the Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer Statement of Translational Relevance (2015) (0)
- Abstract P3-07-08: Exposure-adjusted incidence rates (EAIRs) of adverse events (AEs) from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in HR+/HER2- metastatic breast cancer (MBC) (2023) (0)
- Highlights in metastatic breast cancer from SABCS 2022. (2023) (0)
- Iniparib (2020) (0)
- 236P Real-world comparative effectiveness of palbociclib plus letrozole vs letrozole in older patients with metastatic breast cancer (2021) (0)
- Durvalumab With Olaparib and Paclitaxel for High-Risk HER2-Negative Stage II/III Breast Cancer: Results From the Adaptively Randomized I-SPY2 Platform Trial (2020) (0)
- CLO20-039: Patient (pt)-Reported Outcomes (PRO) in Patients With HER2-Negative Locally Advanced/Metastatic Breast Cancer (LA/mBC) and a Germline BRCA1/2 Mutation (gBRCA1/2 mut) Receiving Talazoparib vs. Physician’s Choice of Chemotherapy (PCT): A Focus on EMBRACA Racial Subgroups (2020) (0)
- Phosphoinositide 3-kinase inhibition in the treatment of hormone receptor-positive breast cancer. (2019) (0)
- Abstract PD2-07: Impact of using cross-platform gene expression profiling technologies and computational methods for intrinsic breast cancer subtyping in PALOMA-2 and PALLET (2022) (0)
- 156P Matching-adjusted indirect comparison (MAIC) of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer (HR+/HER2 ABC) (2020) (0)
- Information preferences of women with triple-negative breast cancer (TNBC). (2015) (0)
- Combinatorial Immunotherapies Overcome MYC-Driven Immune Evasion (2021) (0)
- Targeted Therapy for Breast Cancer: A Focus on HER2/neu and Antiangiogenic Therapy (2009) (0)
- Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid (2021) (0)
- Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer (2022) (0)
- Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness (2021) (0)
- Abstract D078: Unlocking the vault: Can 2nd opinions by Comprehensive Cancer Center breast oncologists improve treatment quality for African Americans? (2020) (0)
- Highlights in metastatic breast cancer from the 2020 San Antonio Breast Cancer Symposium: commentary. (2021) (0)
- Patient-centered dosing: oncologists’ perspectives about treatment-related side effects and individualized dosing for patients with metastatic breast cancer (MBC) (2022) (0)
- Abstract PS10-09: Real-world analysis of concomitant medication use with potential drug-drug interactions (DDI) in patients with metastatic breast cancer (MBC) treated with cylin dependent kinase (CDK) 4/6 inhibitors (2021) (0)
- Management of Metastatic Breast Cancer (2015) (0)
- Alpelisib (ALP) + endocrine therapy (ET) by last prior therapy in patients (pts) with PIK3CA-mutated hormone-receptor positive (HR+) human epidermal growth factor receptor-2-Negative (HER2–) advanced breast cancer (ABC): Additional study cohort in BYLieve (2019) (0)
- 274PBaseline characteristics and first-line (1L) treatment of patients with HER2+ metastatic breast cancer (MBC) from the SystHERs registry (2017) (0)
- A model-based approach to dose optimization of neurotoxic chemotherapy for metastatic breast cancer (MBC). (2015) (0)
- Phase 3 ENABLAR-2 study to evaluate enobosarm and abemaciclib combination compared to estrogen-blocking agent for the second-line treatment of AR+, ER+, HER2- metastatic breast cancer in patients who previously received palbociclib and estrogen-blocking agent combination therapy. (2022) (0)
- Abstract P5-13-36: Germline BRCA1/2 and other predisposition genes in high-risk early-stage HR+/HER2- breast cancer (BC) patients treated with endocrine therapy (ET) with or without palbociclib: A secondary analysis from the PENELOPE-B study (2022) (0)
- Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response (2015) (0)
- Immunotherapy for early triple negative breast cancer: research agenda for the next decade (2022) (0)
- TIM-3 Regulates CD 103 + D endritic Cell Function and Response to Chemotherapy in Breast Cancer Graphical (2018) (0)
- Combined peripheral natural killer (NK) cell and circulating tumor cell (CTC) enumeration to enhance prognostic efficiency in patients (pts) with triple-negative breast cancer (TNBC). (2017) (0)
- 100P Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, in patients with metastatic AR+/ER+ breast cancer resistant to estrogen receptor targeted agents and CDK 4/6 inhibitor in a phase II clinical study (2021) (0)
- Circulating tumor cell and endothelial cell data from a phase II evaluation of lapatinib and bevacizumab in HER2-overexpressing metastatic breast cancer. (2009) (0)
- Treatment (tx) patterns and clinical outcomes for patients (pts) with de novo versus recurrent HER2+ metastatic breast cancer (MBC). (2013) (0)
- Abstract OT3-19-02: Introducing an electronic platform to collect patient reported outcomes in the I-SPY 2 trial, a neoadjuvant clinical trial (2020) (0)
- Abstract GS5-04: Identification of symptoms that are associated with irAEs in the I-SPY clinical trial (2023) (0)
- Pazopanib (PZ) plus endocrine therapy as treatment for hormone resistant advanced breast cancer (ABC). (2020) (0)
- Abstract P2-02-06: Biomarker analysis by next generation circulating tumor DNA (ctDNA) sequencing in patients with advanced breast cancer (2018) (0)
- Abstract OT1-18-08: Randomized phase II trial of pembrolizumab/carboplatin vs. carboplatin alone for breast cancer with chest wall recurrence: TBCRC044 (2022) (0)
- Abstract GS5-03: Evaluation of anti-PD-1 Cemiplimab plus anti-LAG-3 REGN3767 in early-stage, high-risk HER2-negative breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL (2023) (0)
- Reply to the letter to the editor 'Everolimus, when combined with exemestane, adds toxicity with minimal benefit for women with breast cancer' Tannock and Pond. (2014) (0)
- Evaluation of the Pathways for Survivors program to address breast cancer survivorship associated distress (2021) (0)
- Abstract PD04-10: Genome-Wide Copy Number Analysis of Circulating Tumor Cells (CTCs) from Metastatic Breast Cancer Patients (2010) (0)
- Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer. (2023) (0)
- Abstract P2-13-03: Variation in the use of mastectomy (MAST) in women with small node negative breast cancer (BC) treated at US academic institutions (2015) (0)
- Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): subgroup analysis of 2 randomized phase 3 studies (2018) (0)
- Abstract P1-02-06: Assigning luminal A versus luminal B subtype using the Ki67 index in patients with hormone receptor positive (HR+) breast cancer enrolled in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657) (2013) (0)
- Little Downside. (2022) (0)
- Using diagnosis codes in claims data to identify cohorts of breast cancer patients following initial treatment (2020) (0)
- Abstract P1-02-07: Discordance for low and intermediate levels (1+ or 2+ by IHC) of HER2 protein expression in the phase III PRESENT trial (2013) (0)
- Abstract P5-16-01: Assessment of health-related quality of life by clinical response from the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC) (2022) (0)
- Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial (2022) (0)
- High-dimensional immune cell profiling of cerebrospinal fluid from patients with metastatic breast cancer and leptomeningeal disease (2023) (0)
- A PLAIN-LANGUAGE SUMMARY OF THE SOLAR-1 TRIAL: STUDYING ALPELISIB WITH FULVESTRANT IN PATIENTS WITH HR+, HER2– ADVANCED BREAST CANCER WHO HAD PREVIOUSLY RECEIVED AN AROMATASE INHIBITOR (2019) (0)
- Abstract P5-07-03: The Association Between Symptom Severity and Physical Function among Participants in I-SPY2 (2023) (0)
- Title : Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients (2012) (0)
- Addition of pazopanib (PZ) to endocrine therapy in hormone resistant advanced breast cancer (ABC). (2016) (0)
- Biosimilars for HER2-Positive Breast Cancer (2019) (0)
- Abstract P3-08-18: Association of tamoxifen use and ovarian aging in patients with invasive or pre-invasive breast cancer (2013) (0)
- Abstract P5-14-08: Effectiveness of palbociclib plus letrozole vs letrozole in US Hispanic and African American patients with metastatic breast cancer: Flatiron database analysis (2022) (0)
- Answers Are in the Blood: cfDNA to Enhance Precision Medicine for Breast Cancer (2021) (0)
- Identifying tests related to breast cancer care in claims data (2019) (0)
- Abstract LB170: Artificial intelligence-assisted morphology-based detection and enrichment of malignant effusion tumor cells as a method for molecular profiling (2023) (0)
- Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2. (2022) (0)
- Combination of lapatinib and capecitabine provides significant benefit in metastatic disease: Comment (2006) (0)
- ME01 Frontiers in Immunotherapy (2022) (0)
- 03 - PATIENT-REPORTED OUTCOMES (PROS) IN PATIENTS (PTS) WITH PIK3CA-MUTATED HORMONE RECEPTOR-POSITIVE (HR+), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2–NEGATIVE (HER2–) ADVANCED BREAST CANCER (ABC) FROM SOLAR-1 (2019) (0)
- Abstract OT2-14-01: CAPItello-292: A phase Ib/III study of capivasertib, palbociclib and fulvestrant, versus placebo, palbociclib and fulvestrant, for endocrine therapy-resistant HR+/HER2− advanced breast cancer (2022) (0)
- Abstract 2703: Leukocyte complexity in human breast cancer and response to chemotherapy (2011) (0)
- Preferences in educational topics of interest to women with triple-negative breast cancer: The role of age, race/ethnicity, and stage at diagnosis in topic selection. (2015) (0)
- Abstract P3-02-02: FES-dedicated breast PET uptake in early-stage ER+ breast cancers (2022) (0)
- Current status of the implementation of gene expression testing in breast cancer management in the United States. (2013) (0)
- Abstract A006: Can expert second opinions reduce treatment disparities for African American breast cancer patients? An exploratory study (2020) (0)
- Abstract PS2-19: Circulating tumor cell (CTC) enumeration in a phase II trial of pazopanib in addition to endocrine therapy in patients with hormone resistant advanced breast cancer (ABC) (2021) (0)
- PO139 RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B (RANK) EXPRESSION IN PRIMARY BREAST CANCER CORRELATES WITH RECURRENCE FREE SURVIVAL AND DEVELOPMENT OF BONE METASTASES IN THE I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657) (2015) (0)
- IMpassion130: Efficacy in immune biomarker subgroups of atezolizumab plus nab-paclitaxel in patients with triple-negative BC (2019) (0)
- Assays of circulating tumor cells and outcome in the triple-negative breast cancer trial TBCRC001. (2009) (0)
- Circulating and Disseminated Tumor Cells from Solid Tumors—Research and Clinical Aspects (2009) (0)
- Abstract PD13-06: PD13-06 Long-Term and Very-Long-Term Disease Control in Patients From BYLieve Study Cohort A With PIK3CA-Mutant, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Advanced Breast Cancer (2023) (0)
- When to Treat, With What, and for How Long: That Is the Question! (2016) (0)
- Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients (2021) (0)
- In Reply (2021) (0)
- Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3 (2022) (0)
- Abstract PD18-02: Adjuvant Paclitaxel and Trastuzumab Trial (APT) for Node-Negative, Human Epidermal Growth Factor Receptor 2–Positive (HER2+) Breast Cancer: final 10-year analysis (2023) (0)
- Reply to Z.R. McCaw et al. (2022) (0)
- Abstract P4-16-07: Selective use of post-mastectomy radiation therapy in the neoadjuvant setting (2012) (0)
- PS2-2 KEYNOTE-355 Asian subset: Pembrolizumab + chemotherapy vs placebo + chemotherapy for triple-negative breast cancer (2022) (0)
- Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST? (2021) (0)
- Abstract OT1-07-05: TROPiCS-02: phase 3 study of Sacituzumab Govitecan (IMMU-132) in relapsed/refractory hormonal receptor-positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (MBC) (2020) (0)
- Identification of distinct subgroups of patients with arm pain following breast cancer surgery (2013) (0)
- Accelerating progress from advanced to early breast Cancer (2021) (0)
- Plasma PIK 3 CA ctDNA specific mutation detected by next generation sequencing is associated with clinical outcome in advanced breast cancer (2018) (0)
- Concerns About Methodology of a Trial Investigating Vaginal Health During Aromatase Inhibitor Therapy for Breast Cancer-Reply. (2017) (0)
- Abstract OT-30-02: Phase II study of talazoparib, a PARP inhibitor, in somaticBRCA1/2mutant metastatic breast cancer (2021) (0)
- Contributors (2012) (0)
- Biomarker analysis from a phase I study using gedatolisib+palbociclib+hormone therapy in ER+/HER2- metastatic breast cancer (mBC). (2020) (0)
- Current treatment options for metastatic breast cancer: what now? (2011) (0)
- Abstract P4-09-12: Baseline and End-of-Treatment Biomarkers in Patients With PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From BYLieve Study Cohorts A and B (2023) (0)
- Treatment selection for patients with low and equivocal ER status (2019) (0)
- 322P Prognostic factors for overall survival (OS) in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (HR+/HER2− ABC): Analyses from PALOMA-3 (2020) (0)
- 181TiP Xentuzumab (Xe) in combination with everolimus (Ev) and exemestane (Ex) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) and non-visceral involvement (XENERA™-1) (2020) (0)
- Abstract 4949: Combined immunochemotherapy for poor prognosis breast cancer. (2013) (0)
- Sacituzumab govitecan meets primary endpoint (2022) (0)
- Abstract LB111: Comparison of the predictive and prognostic significance of circulating tumor DNA in patients with high risk HER2-negative breast cancer receiving neoadjuvant chemotherapy (2022) (0)
- Expert Discussion: Predictive Markers (2021) (0)
- Abstract 5578: Genomic and expression profiling reveals molecular heterogeneity of disseminated tumor cells in early breast cancer (2018) (0)
- Abstract P1-16-05: Oraxol + Encequidar (OPac+E) vs IV paclitaxel (IVPac) in the treatment of patients with metastatic breast cancer (mBC) (Study KX-ORAX-001): Subgroup survival analysis of patients with hepatic dysfunction (2022) (0)
- AntiemesisPractice Guidelines in Oncology TM (2009) (0)
- Abstract PS7-61: The Neat-HER Virtual Registry: Results on HER2+ breast cancer patients receiving neratinib as extended adjuvant therapy (2021) (0)
This paper list is powered by the following services:
Other Resources About Hope Rugo
What Schools Are Affiliated With Hope Rugo?
Hope Rugo is affiliated with the following schools:
- Medical University of Vienna
- Indiana University
- University of Oxford
- Loyola University Chicago
- University of California, San Francisco
- Massachusetts General Hospital
- New York University
- Duke University
- University of Liverpool
- Université libre de Bruxelles
- Washington University in St. Louis
- Indiana University Bloomington
- Autonomous University of Barcelona
- University of California, Irvine
- Stanford University
- Rush University
- Harvard University
- Heidelberg University
- University of Pennsylvania
